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ABSTRACT:
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated 
by genetic alterations in upstream signaling molecules such as receptor tyrosine 
kinases (RTK). Certain components of these pathways, RAS, NF1, BRAF, MEK1, DUSP5, 
PP2A, PIK3CA, PIK3R1, PIK3R4, PIK3R5, IRS4, AKT, NFKB1, MTOR, PTEN, TSC1, 
and TSC2 may also be activated/inactivated by mutations or epigenetic silencing. 
Upstream mutations in one signaling pathway or even in downstream components 
of the same pathway can alter the sensitivity of the cells to certain small molecule 
inhibitors. These pathways have profound effects on proliferative, apoptotic and 
differentiation pathways. Dysregulation of components of these cascades can 
contribute to: resistance to other pathway inhibitors, chemotherapeutic drug 
resistance, premature aging as well as other diseases. This review will first describe 
these pathways and discuss how genetic mutations and epigenetic alterations can 
result in resistance to various inhibitors. 
INTRODUCTION
This review is an updated and expanded version of 
a previous review on this topic [1]. This current review 
now discusses some of the types and classes of mutations 
which occurs in these pathways and their biochemical 
importance in terms of therapy. We will focus on the 
recent advancements in elucidating the roles of the Ras/
Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways and 
the types and classes of mutations which occur in these 
pathways. Since the discovery of the RAS, RAF, MEK, 
PIK3CA, and AKT oncogenes and NF1, DUSP5, PP2A, 
PTEN, TSC1 and TSC2 tumor suppressor genes, the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
signaling cascades have been extensively investigated 
with the ultimate goal of determining how these genes 
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become activated/inactivated and whether it is possible 
to suppress their activity in cancer and other growth-
related diseases [1-6]. Furthermore these pathways are 
also frequently implicated in the resistance and sometimes 
sensitivity to therapy [1-6]. Research has also resulted 
in the development of inhibitors that target critical 
components of these pathways with the ultimate goal to 
increase patient survival or in some cases to prevent or 
impede the development of other diseases (e.g., obesity, 
diabetes and premature aging) [7-9]. 
Before we discuss the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR signaling cascades, it is 
important to define some genetic terms as they are critical 
to understanding the importance of these pathways and the 
classes of genes and mutations that occur in components 
of these cascades. We briefly discuss certain classes of 
genes which play key roles in the development of cancer. 
Caretaker genes are involved in genomic stability and 
normally function to suppress the mutation rate [10]. 
Caretaker mutations occur mainly in tumor suppressor 
genes, such as TP53 (p53) and PTEN. TP53 and PTEN 
are caretaker genes. Caretaker genes help maintain the 
integrity of the genome.
Gatekeeper genes directly regulate cell growth and 
their loss can lead to tumorigenesis. They encode critical 
proteins which can regulate growth or the induction of 
apoptosis. Many genes fall into this class including: 
MAPK3/MAPK1 (ERK1/ERK2), TP53, PTEN, NF1, TSC1 
TSC2, MTOR (mTOR), EIF4E (eIF4E). Obviously some 
genes can fall into multiple classifications [11]. 
The concept of a driver mutation is very important 
in cancer. If the driver mutation can be successfully 
targeted that may lead to elimination of the cancer. This 
is a mutation that is statistically enriched in a particular 
cancer and usually thought to be one of the first events in 
the malignant transformation of those particular cells to 
cancer cells [12]. Examples of driver mutations in these 
two pathways include RAS, NF1, BRAF, MEK1, PIK3CA 
(PI3K), and PTEN.
A second class of mutations is passenger mutations 
[6]. Passenger mutations may occur by different 
mechanisms. Passenger mutations may occur upon 
genomic deletion of the region of the chromosome which 
contains the driver mutation [6]. This has been observed 
in glioblastoma which have the glycolytic gene enolase 1 
(ENO1) gene deleted as it is in the neighborhood of the 
1p36 tumour-suppressor locus [6]. ENO1 is a member of a 
gene family and there are two other ENO genes. Normally, 
the cell can survive in the presence of ENO1 deletion, 
however, if ENO2 is silenced, the cancer cell with the 
ENO1 deletion dies. This provides a selective approach to 
kill cancer cells, illustrating the significance of identifying 
passenger mutations. 
Next we discuss types of mutations which can 
result in therapeutic resistance. Gatekeeper mutations 
often occur in genes (often protein kinases) in either 
the inhibitor binding site or in the ATP binding site of 
the protein. They are detected in BRAF, ERK, BCRABL, 
and epidermal growth factor receptor (EGFR) and can 
mediate resistance to small molecule inhibitors as that is 
often where they bind and inhibit activity. They have also 
been detected in PIK3CA but not necessarily in the hot 
spot locations [13,14]. Hot spot locations are regions of 
the gene where mutations are most frequently detected and 
they can confer a biochemical advantage to the cells which 
allows abnormal growth.
A synthetic lethal mutation refers to a mutation that 
occurs in a second gene and results in the death of the 
cell. This terminology was coined by yeast geneticists. 
Synthetic lethal screening has resulted in the elucidation 
of how certain gene products interact with other gene 
products forming biochemical pathways [15,16]. 
For example, when there is an activated oncogene or 
inactivated tumor suppressor gene present in a cell which 
frequently leads to the abnormal proliferation of the cells, 
a synthetic lethal mutation may occur at a second gene 
which results in the death of the transformed cell [17-19]. 
In essence, there is the loss of a biochemical interaction 
between the mutant oncogene or tumor suppressor gene 
and the second gene and the cell dies. Hence the second 
mutation is referred to as synthetic lethal. In terms of 
the Ras/Raf/MEK/ERK pathway, which proliferates 
in response to mutant KRAS, silencing of genes such 
as voltage-dependent anion channel (VDAC1), serine/
threonine kinase 33 (STK33), TANK- binding kinase 1 
(TBK) or polo-like kinase-1 (PLK1) results in synthetic 
lethal interactions [15]. Synthetic lethal interactions are 
frequently identified by screening siRNA or shRNA 
libraries. In the PI3K/PTEN/Akt/mTOR pathway, a 
synthetic lethal interaction is observed in renal cell 
carcinoma (RCC) cells which lack the von Hippel–Lindau 
tumor suppressor protein (VHL) as treatment of the cells 
with rapamycin, an inhibitor of mTORC1 which the tumor 
cells are dependent on, results in death [15,16].
Lineage-specific mutations occur in genes which 
are abnormally expressed in certain types of cancers. 
In certain cell types, the cells become addicted to a 
lineage-specific gene as well as the mutant oncogene(s). 
An example is observed in melanoma cells which have 
mutant BRAF. These cells often have increased expression 
of the microphthalmia-associated transcription factor 
(MITF) which is believed to allow the survival of cells 
of the melanocyte lineage. MITF is sometimes amplified 
in certain subsets of melanoma cells and cooperates 
with mutant BRAF to regulate melanoma proliferation. 
In normal melanocytes, MITF induces cell cycle arrest, 
whereas in melanoma cells, mutant B-Raf may stimulate 
MITF transcription while this stimulation of transcription 
does not occur in normal melanocytes [20].
Oncogene-addiction is a widely-used term to 
describe the transformed cells addiction to a particular 
gene or pathway [20-27]. The transformed cells 
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Figure 1: Activation of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR Pathways by Genetic Mutations. 
Activation of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways can occur by upstream mutations in growth factor 
receptors or by mutations in upstream kinases and coupling molecules. In addition, intrinsic members of the two pathways are frequently 
mutated in human cancer. Genes in the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways that have activating mutations 
detected in human cancer and proliferative diseases are indicated in red ovals. Four mutations have been detected in the RHEB gene in 903 
samples present in the Sanger Institute COSMIC database. Four mutations have been observed in the p70S6K gene (RBS6KB1) out of 1047 
samples examined (Sanger Institute COSMIC database. Also loss of tumor suppressor genes such as PTEN, PP2A, NF1 DUSP5, TSC1, 
TSC2 can contribute to activation of certain pathways. These are indicated in black octagons if they are phosphatases or black squares if 
they are coupling molecules. Other kinases not frequently mutated in human cancer are indicated in green symbols. PIP2 and PIP3 are 
indicated in yellow ovals. The 4E-BP1and eIF-4E proteins are indicated in purple ovals. mTORC1 phosphorylates the unc-51-like kinase 1 
(ULK1) which results in the suppression of autophagy. ULK1 is indicated in a black oval. The mTORC1 inhibitor prevents phosphorylation 
of ULK1 and autophagy can occur. Red arrows indicate activating events in pathways. Black arrows indicate inactivating events in pathway. 
Activating phosphorylation events are depicted in red circles with Ps with a black outlined circle. Inactivating phosphorylation events are 
depicted in black circles with Ps with a red outlined circle. 
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frequently contain a mutation at a particular oncogene, 
or correspondingly, inactivation of a tumor suppressor 
gene. The cells become addicted to the consequences of 
that mutation and grow under conditions where a normal 
cell would not persist [22]. Many malignant melanoma 
cells become addicted to mutant BRAF for proliferation 
[20]. Likewise either mutation of PIK3CA or silencing of 
PTEN and subsequent activation of Akt is a frequent form 
of oncogene addiction in many tumor types [1,2,20-27].
Oncogene bypass occurs when a cell bypasses the 
signal transduction component it normally depended 
upon for survival [4]. This has been observed in certain 
cells which were normally dependent upon EGFR for 
survival, however, when upon exposure to an EGFR 
inhibitor, cells emerged which displayed amplification 
of another oncogene, the MET oncogene (MNNG-HOS 
transforming gene) which allowed the growth of the cells 
in the presence of the EGFR inhibitor [22].
Kinase switching is a similar event. An example is 
when cells with the BRAF V600E mutation were cultured 
in the presence of the B-Raf inhibitor SB-590885, 
inhibitor-resistant cells arose which utilized the related 
Raf-1 and A-Raf isoforms [28]. The genetic mechanisms 
for oncogene bypass and kinase switching as well as many 
of the changes in inhibitor-resistant cells are complicated 
and may result from the outgrowth of a minority of the 
cells present in the original tumor or cell line. 
Oncogenic shock is a term that is used to describe 
the biochemical consequences of inhibiting the oncogene. 
Interestingly, it has been observed that upon inactivation 
of the oncogene responsible for survival, the pro-survival 
and pro-apoptotic signals decay at different rates. In 
absence of the oncogene responsible for the oncogene 
addiction phenotype, the pro-survival signals decay more 
rapidly than the pro-apoptotic signals. This has led to the 
concept of oncogenic shock and provides the basics for the 
success of certain inhibitors in suppressing the growth of 
oncogene-transformed cells [25]. Oncogenic shock may be 
connected with the translation of “weak mRNAs” which 
are regulated by the mTOR complex 1 (mTORC1) (see 
below). Both the Ras/Raf/MEK/ERK and PI3K/PTEN/
Akt/mTOR pathways interact to regulate the activity of 
the mTORC1 complex. The half-lifes of proteins such as 
Akt and ERK are very short (within minutes), while the 
half-lifes of pro-apoptotic signals are much longer (hours). 
The decreased activity of Akt and ERK proteins will have 
a direct effect on the translation of weak mRNAs which 
often encode growth factors and other important proteins 
regulating cell growth (e.g., c-Myc). This is one reason 
why targeting the Ras/Raf/MEK/ERK and PI3K/PTEN/
Akt/mTOR pathways has such profound effects on cell 
growth.
Non-oncogene addiction is a more recently devised 
term to describe the addiction of a cell on another gene 
which is not an oncogene per se [26]. For example, 
rapamycin and modified rapamycins (rapalogs) target 
mTORC1 which is not normally considered an oncogene, 
but the cells are dependent upon the mTORC1 complex 
for their survival. RCC which lack the pVHL tumor 
suppressor protein exhibit non-oncogene addiction [27]. 
Now that we have discussed some general genetic terms, 
we can discuss in more detail the Ras/Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR pathways.
The Ras/Raf/MEK/ERK Pathway
Usually signaling commences upon ligation of a 
growth factor/cytokine/interleukin/mitogen (ligand) to 
its cognate receptor at the cell surface. This event can 
result in the activation of many downstream signaling 
cascades including the Ras/Raf/MEK/ERK and Ras/
PI3K/PTEN/Akt/mTOR pathways. These cascades can 
further transmit their signals to the nucleus to control gene 
expression, to the translational apparatus to enhance the 
translation of “weak” mRNAs, to the apoptotic machinery 
to regulate apoptosis or to other events involved in 
the regulation of cellular proliferation (for example, 
interactions with the p53 pathway to regulate cell cycle 
progression). Regulation of the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR pathways is mediated by 
a series of kinases, phosphatases, GTP:GDP exchange 
and scaffolding proteins. There are also many tumor 
suppressor proteins which interact with these cascades 
which frequently serve to fine tune or limit activity (e.g., 
PTEN, RKIP, PP2A, DUSP5, DUSP6, TSC1, TSC2). 
Mutations occur in many of the genes in these pathways 
leading to uncontrolled regulation and aberrant signaling 
[5,28-32]. Certain of these tumor suppressor genes can 
be regulated by oncogenic micro (mi) RNAs [33]. An 
overview of the effects of mutations and the activation of 
the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
signaling pathways and how they interact is presented in 
Figure 1. In this review, we will point out which genes 
are abnormally expressed in human cancer to illustrate the 
importance of these genes and pathways. 
Following stimulation of a growth factor receptor 
(GFR), a Src homology 2 domain containing protein (Shc) 
adaptor protein becomes associated with the C-terminus 
of the activated GFR, e.g.,  EGFR, insulin like growth 
factor-1 receptor (IGF-1R), vascular endothelial growth 
factor receptor (VEGFR) and many others [1-3, 34-38]. 
EGFR mutations can contribute to transformation of 
multiple cell lineages and these alterations are considered 
driver mutations
Shc recruits the growth factor receptor-bound 
protein 2 (Grb2) protein and the son of sevenless (SOS) 
homolog protein [a guanine nucleotide exchange factor 
(GEF)], resulting in the loading of the membrane-bound 
GDP:GTP exchange protein (GTPase) Ras with GTP [1,2]. 
RAS is frequently mutated in many diverse human cancers. 
RAS mutations are often driver mutations. GEFs promote 
Ras activation by displacing GDP from Ras which leads 
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Figure 2: Regulatory Loops in the Ras/Raf/MEK/ERK Pathway.  ERK can phosphorylate members of the Ras/Raf/MEK/
ERK pathway and even upstream EGFR. Sometimes these phosphorylation events mediated by ERK can inhibit the activity of the 
phosphorylated molecule. ERK can also phosphorylate Ets which can lead to transcription of the DUSP genes which in turn can inactivate 
ERK by dephosphorylation. PP2A can also suppress Raf activity by dephosphorylation.  The activated EGFR is depicted in blue. Kinases 
are indicated by green ovals.  Phosphatases are indicated by black octagons. Coupling molecules are indicated by orange ovals. Ras is 
indicated by a purple oval. The transcription factors Ets is indicated by a yellow diamond. The activated EGFR is depicted in blue.  Red 
arrows indicate activating events in pathways. Black arrows indicate inactivating events in pathway. Activating phosphorylation events are 
depicted in red circles with Ps with a black outlined circle. Inactivating phosphorylation/dephosphorylation events are depicted in black 
circles with Ps with a red outlined circle.
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to GTP binding. 
Ras activation is suppressed by the GTPase 
activating proteins (GAPs) that stimulate the GTPase 
activity of Ras. There are two prominent GAP proteins, 
p120GAP and NF1. NF1 is a tumor suppressor gene and 
has both driver and gatekeeper gene functions. Germline 
mutations at NF1 lead to neurofibromatosis [29]. 
Ras can also be activated by GFRs, such as insulin 
receptor (IR), via intermediates like insulin receptor 
substrate (IRS) proteins that bind Grb2 [34]. IRS4 has 
recently been documented to be mutated in melanoma [5]. 
Ras:GTP then recruits the serine/threonine (S/T) kinase 
Raf to the membrane where it becomes activated, likely 
via a Src-family tyrosine (Y) kinase [1,2]. Recently Ras-
mediated Raf-1 activation has been shown to be dependent 
on calcium/calmodulin-dependent protein kinase II 
(CaMK-II) which phosphorylates Raf-1 at S338 in some 
experimental stimulation conditions [EGF, fetal bovine 
serum (FBS) treatment]. This dependency does not appear 
to occur with regards to B-Raf activation [39].
Both RAS and RAF are members of multi-gene 
families and there are three Ras members (KRAS, NRAS 
and HRAS) [1-4] and three RAF members [BRAF, RAF1 
(a.k.a c-Raf) and ARAF) [1-3].  BRAF is frequently 
mutated in melanomas and certain other cancers and these 
mutations are frequently driver mutations [40]. 
Raf-1 can be regulated by dephosphorylation by 
the protein serine/threonine phosphatase 2A (PP2A) and 
others [41,42]. PP2A has been reported to positively and 
negatively regulate Raf-1. PP2A is also considered a 
tumor suppressor gene and has gatekeeper gene functions 
[43]. 
Raf phosphorylates and activates the mitogen-
activated protein kinase kinase-1 (MEK1) (a dual 
specificity kinase (T/Y) on S/T residues [1-4]). Other 
proteins such as kinase suppressor of Ras (KSR) have 
recently been shown to phosphorylate MEK1 [44-48]. 
KSR has scaffolding properties and interacts with Raf, 
MEK and ERK which regulate ERK activation [44-48]. 
KSR can form dimers with various Raf proteins which 
alter the effects of Raf inhibitors. KSR1 competes with 
Raf-1 for Raf inhibitor-induced binding to B-Raf which 
decreases the normal ERK activation observed after Raf-
inhibitor treatment [47]. 
MEK1 phosphorylates extracellular signal regulated 
kinases 1/2 (ERK1 and 2) at specific T /Y residues [1-4]. 
MEK1 was originally not thought to be mutated frequently 
in human cancer. However, recent large scale mutation 
screening studies and studies aimed at determining 
mechanisms of resistance to small molecule inhibitors 
have observed that MEK1 is mutated in certain human 
cancers and also is mutated in certain inhibitor-resistant 
cells. MEK1 is also considered to be a driver oncogene 
in certain cancers [49]. Rac (Ras related gene) and p21-
activating kinases (PAK) can also regulate MEK/ERK 
activation [50,51]. 
Activated ERK1 and ERK2 S/T kinases 
phosphorylate and activate a variety of substrates, 
including p90 Ribosomal six kinase-1 (p90Rsk1) and this 
pathway has been implicated in cancer progression [1-3]. 
ERK1/2 are considered by some as gatekeeper genes. ERK 
also phosphorylates MAPK signal integrating kinases 
(Mnk1/2) which can in turn phosphorylate (eukarytotic 
translation initiation factor 4E) eIF4E, a key protein 
involved in the translation of difficult mRNAs [1-3]. 
EIF4E is considered to be a gatekeeper gene.
p90Rsk1 can activate the cAMP response element 
binding protein (CREB) transcription factor as well as 
proteins involved in regulation of protein translation (e.g., 
Mnk-1, p70 ribosomal S6 kinase (p70S6K), eukaryotic 
translation initiation factor 4B, (eIF4B), and ribosomal 
protein S6 (rpS6) [52].
The number of ERK1/2 substrates/targets is 
easily in the hundreds. These substrate/targets include 
different types of molecules including: other kinases, 
phosphatases, growth factor receptors, cytokines, cell 
cycle regulator proteins, transcription factors, or proteins 
involved in mRNA translation or apoptosis. Suppression 
of MEK and ERK can have profound effects on cell 
growth, inflammation and aging. Activated ERK can also 
phosphorylate “upstream” Raf-1 and MEK1 which alter 
their activity. Depending upon the site phosphorylated on 
Raf-1, ERK phosphorylation can either enhance [53] or 
inhibit [54] Raf-1 activity. In contrast, some studies have 
indicated that when MEK1 is phosphorylated by ERK, 
its activity decreases [55]. Recent studies indicate that 
ERK does not negatively feedback inhibit B-Raf [56]. 
ERK also phosphorylates SOS at multiples sites leading 
to the dissociation of SOS from GRB2 and preventing 
Ras activation [4, 57]. ERK can also phosphorylate 
EGFR and suppress its activity [58]. The dual specificity 
phosphatases (DUSP) (aka MKPs) are transcriptionally 
induced by ERK phosphorylation of transcription factors 
(e.g., Ets) [59]. The DUSPs serve as negative feedback 
regulators to suppress ERK activity. Some of the events 
induced by ERK phosphorylation are rapid, such as post-
trasnlational modification, while other events require gene 
transcription and translation (e.g., ERK phosphorylation 
of Ets which induces transcription of DUSPs). The 
DUSPs are potentially tumor suppressor genes and DUSP 
mutations have been detected in various cancers [60]. An 
overview of the regulatory loops in the Ras/Raf/MEK/
ERK pathway is presented in Figure 2.  
The Raf/MEK/ERK pathway exhibits properties 
of a negative feedback amplifier (NFA). In essence, NFA 
signaling is similar in biological design to those used in 
electronic circuits. NFAs in electronic circuits optimize 
robustness, stabilization of signal and linearization of non 
linear signal amplification. These properties of the Raf/
MEK/ERK NFA are important in determining activation 
kinetics, response to drugs and various other downstream 
effects of activated ERK [56]. 
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 Phosphorylation events induced by ERK serve 
to alter the stability and/or activities of the proteins. 
These examples of feed-back loops become important in 
consideration of whether to just target MEK or to target 
both Raf and MEK in various cancers. It is important that 
the reader realize that certain phosphorylation events can 
either inhibit or repress the activity of the affected protein. 
This often depends on the particular residue on the protein 
phosphorylated which can confer a different configuration 
to the protein or target the protein to a different subcellular 
localization that may result in proteasomal degradation or 
association with certain scaffolding proteins.
There are numerous scaffolding/chaperonin proteins 
which interact with various components of the Raf/MEK/
ERK cascade (e.g., 14-3-3) [61], MEK partner-1 (MP-
1) [62], heat shock protein-90 (HSP-90) [63], KSR [64] 
Raf kinase inhibitory protein (RKIP) [65]. Heat shock 
proteins such as HSP-90 are considered caretakers as they 
normally serve to protect the activity of client proteins 
[66, 67]. Mutations at KRAS will confer sensitivity to 
Figure 3: Effects of ERK and Akt on Regulatory Processes.  ERK and Akt can phosphorylate many targets which serve to 
regulate cell proliferation.  In Panel A, some of the effects of ERK and Akt on the translation of highly structured mRNAs are indicated. 
Kinases are indicated in green ovals or rectangles (mTORC1 and mTORC2 complexes). TSC1 and TSC2 are indicated in black squares. 
Rheb is indicated in a dark blue oval. mTOR interacting proteins which positively regulate mTOR activity are indicated in yellow ovals. 
mTOR interactiving proteins which negatively regulate mTOR activity are indicated in black ovals. mRNA initiation factors and proteins 
associated with the ribosome are indicated in purple ovals. In Panel B, some of the effects on the regulation of gene expression by ERK and 
Akt phosphorylation are indicated. Transcription factors activated by either ERK or Akt phosphorylation are indicated in yellow diamonds. 
The Foxo transcription factor that is inactivated by Akt phosphorylation is indicated by a black diamond.  Beta-catenin is indicated in 
an orange rectangle.  In Panel C, some of the effects of ERK and Akt phosphorylation on apoptotic regulatory molecules are indicated. 
Molecules such as Mcl-1 which are anti-apoptotic and phosphorylated by ERK and Akt are indicated by blue ovals, other anti-apoptotic 
molecule are also indicated by blue ovals. Pro-apoptotic molecules are indicated by black ovals.  Red arrows indicate activating events in 
pathways. Black arrows indicate inactivating events in pathway. Activating phosphorylation events are depicted in red circles with Ps with 
a black outlined circle. Inactivating phosphorylation events are depicted in black circles with Ps with a red outlined circle.
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HSP-90 inhibitors such as geldanamycin, documenting 
the importance of HSP-90 in regulation of this pathway 
[68,69]. 
 RKIP is also considered a metastasis suppressor 
gene in certain cancers and has gatekeeper and caretaker 
effects. Raf-1 activation by Ras has been shown to be 
dependent on the prohibitin protein, a ubiquitously 
expressed protein which may also serve as a chaperonin 
protein [70].
The regulation of ERK1/2 activity in the nucleus 
and cytoplasm is complex as the p38MAPK-alpha splice 
isoform Max-interacting protein (Mxi-2) can bind ERK1/2 
and ensure its translocation into the nucleus and prevent 
both MAPK phosphatase-1 (MKP1) and DUSP5 from 
dephosphorylating ERK1/2 in the nucleus and not the 
cytoplasm. Most phosphatases will probably eventually be 
shown to be tumor suppressor genes. Upon Mxi-2 binding 
ERK1/2, enhanced ERK1/2 activity is detected in the 
nucleus. Mxi-2 prevents the dephosphorylation of ERK1/2 
by MKP1 and DUSP5. This allows activated ERK1/2 to 
phosphorylate the transcription factor c-Myc and other 
critical substrates [71-73].
In the nucleus ERK can phosphorylate transcription 
factors, such as: E twenty-six-like transcription factor 1 
(Elk-1), estrogen receptor (ER), Fos, globin transcription 
factor 1 (Gata-1), c-Myc, signal transducer activation of 
transcription 1 & 3 (STAT1 & 3) and others [1-3,55,74-
76]. These transcription factors bind the promoters of 
many genes, including growth factor and cytokine genes 
that are important in promoting growth and preventing 
apoptosis of multiple cell types. 
ERK can also phosphorylate and modulate the 
activity of the Twist, Snail, Slug, and Zeb1 transcription 
factors either directly or indirectly which can regulate 
cellular proliferation, survival and some can modulate 
epithelial mesenchymal transition (EMT) [77-92]. 
Phosphorylation of the transcription factors by ERK1/2, 
or in some cases the related MAPK, p38MAPK, prevents 
their ubiquitination and results in their stabilization and 
increased activity in the nucleus and ability to promote 
EMT [83-92].
In the nucleus, ERK can also phosphorylate mitogen 
and stress-activated protein kinases (MSKs) [93,94] which 
in turn can phosphorylate transcription factors such as 
activator transcription factor-1 (ATF-1) that is important in 
the regulation of many immediate early genes controlled 
by activating protein-1 (AP-1) [95]. The ternary complex 
factors (TCF) such as Elk-1, Sap-1 and Net are also 
phosphorylated by ERK which results in their activation 
[96,97]. The TCFs form complexes with serum responsive 
factor (SRF) and activate many genes through their serum 
responsive elements (SRE) in their promoter regions 
[98,99].
MSKs also phosphorylate many proteins involved 
in modulating chromatin structure including: Histone 
H3, and (high-mobility-group protein-14) HMG14 which 
can result in the transcription of immediate early genes 
after mitogens/growth factor stimulation [100]. ERK1/2 
can phosphorylate many proteins critical for cytoskeletal 
structure/reorganization including:  calpain (Capn) 
[101], focal adhesion kinase (FAK) [102], myosin light 
polypeptide kinase (MLCK) and paxillin-6 (Pax6) [103]. 
Sometimes phosphorylation by ERK of FAK can result in 
FAK dephosphorylation [104].  
Thus the Ras/Raf/MEK/ERK pathway is important 
in determining cellular shape and mobility/invasion. Under 
certain circumstances, aberrant regulation of this pathway 
can contribute to abnormal cellular growth, mobility and 
invasion which may lead to many abnormalities including; 
autocrine transformation, drug resistance, senescence, 
premature aging, or metastasis [1,2,105-119]. 
Thus the reader begins to understand how the Ras/
Raf/MEK/ERK pathways can regulate the expression of 
many genes involved in the response to growth factors 
and mitogens. Furthermore many of the genes in this 
pathway, as well as other genes that regulate the activity 
of this pathway, have varying abilities to influence cancer 
development. They can sometimes be drivers of cancer 
development, gatekeeper or caretaker genes. An overview 
of the effects of the Ras/Raf/MEK/ERK and PI3K/PTEN/
Akt/mTOR pathways on key regulatory pathways is 
presented in Figure 3.
Mutations or Altered Expression of the Ras/Raf/
MEK/ERK Pathway Components
In our previous reviews [1,3] we have discussed 
in detail the frequency of Ras mutations observed in 
human cancers. Ras mutations have been observed in 
approximately 20 to 30% of human cancers. Often point 
mutations are detected in RAS genes in cancer cells 
from patients which enhance Ras activity. Genome RAS 
amplification or overexpression of Ras, perhaps due 
to altered methylation of its promoter region, are also 
detected in some tumors [1]. The frequency of KRAS 
mutations is very high (~80%) in advanced pancreatic 
cancers [1]. Mutations in Ki-Ras will make cells sensitive 
to HSP90 inhibitors [68,69]. BRAF is mutated frequently 
in melanomas (50-70%) [5,120], papillary thyroid cancers 
(40%) [121], Langerhans’-cell histiocytosis (57%) [122]. 
BRAF is mutated to lesser extent (2-3%) in non small cell 
lung cancers (NSCLC), [123] and colo-rectal cancers 
(CRC) (8%) [124]. Recently BRAF has been observed 
to be frequently mutated (100%) in hairy cell leukemia. 
[125]. BRAF has been observed to be mutated in 8 of 
199 patients (4%) with multiple myeloma and 4 of those 
were mutant at BRAF V600E [126]. Other B-ALL and 
peripheral B cell lymphomas have been observed to have 
low (>3%) frequencies of BRAF mutations, but none of 
these mutants produced the B-Raf V600E protein [127-
130]. Similar mutations were not detected in the Tiacci et 
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Figure 4: Regulatory Loops in the Ras/PI3K/PTEN/Akt/mTOR Pathway. Some of the regulatory interactions in the Ras/
PI3K/PTEN/Akt/mTOR Pathway are indicated. An activated growth factor receptor is indicated in blue. Ras and Rheb are indicated 
in dark blue ovals. IRS1 is indicated in an orange oval. Kinases are indicated in green ovals with the exception of GSK-3beta which 
is indicated in a black oval as it is inactivated by Akt phosphorylation. The p85 regulatory subunit of PI3K is indicated in a red oval. 
Phosphatases are indicated in black octagons. NF1, TSC1 and TSC2 are indicated in black squares. PIP2 and PIP3 are indicated in yellow 
ovals. Phosphatases are indicated in black octagons. mTOR interacting proteins which positively regulate mTOR activity are indicated in 
yellow ovals. mTOR interactiving proteins which negatively regulate mTOR activity are indicated in black ovals. Transcription factors 
activated by either ERK or Akt phosphorylation are indicated in yellow diamonds. The Foxo transcription factor that is inactivated by 
Akt phosphorylation is indicated by a black diamond.  β-catenin is indicated in an orange rectangle. mRNA initiation factors and proteins 
associated with the ribosome are indicated in purple ovals. mTORC1 phosphorylates the unc-51-like kinase 1 (ULK1) which results in the 
suppression of autophagy. ULK1 is indicated in a black oval. The mTORC1 inhibitor prevents phosphorylation of ULK1 and autophagy can 
occur. Red arrows indicate activating events in pathways. Black arrows indicate inactivating events in pathway. Activating phosphorylation 
events are depicted in red circles with Ps with a black outlined circle. Inactivating phosphorylation events are depicted in black circles with 
Ps with a red outlined circle.
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al. study with similar leukemias and lymphomas [125]. A 
recent study detected BRAF mutations in 2/55 (3.6%) of 
large B-cell lymphoma (DLBCL). The authors postulated 
that BRAF may be considered driver mutations for those 
DLBCL [131]. Cancer patients with the BRAF driver 
mutations are postulated to be sensitive to B-Raf inhibitors 
such as vemurafenib, dabrafenib, and GDC-0879.
 Previously it was thought that the MEK and ERK 
genes were not frequently mutated in human cancer. More 
recent analysis has indicated that MEK1 and MEK2 are 
mutated in certain cancers (e.g., ovarian and lung cancers) 
and can be driver mutations [49, 131-134]. Mutations at 
MEK1 are also important in governing the sensitivity/
resistance of certain cells to Raf and MEK inhibitors and 
will be discussed in an accompanying review [134]. 
Upstream components of this pathway are also 
mutated or deregulated  in human cancer [1-4]. Some 
common receptors which are altered in human cancer 
include EGFR, HER2, IGF-1R, PDGFR, VEGF, and 
FGFR2/3 [1-4].
The Ras/PI3K/PTEN/Akt/mTOR Pathway 
Phosphatidylinositol-3-kinase (PI3K) is a 
heterodimeric protein with an 85-kDa regulatory subunit 
and a 110-kDa catalytic subunit (PIK3CA) [1-3, 135-
138]. PIK3CA is frequently mutated in certain cancers 
such as: breast, ovarian, colorectal, endometrial and lung 
[1,14,139] although its role as a driver mutation in these 
cancers remains controversial [140]. Recent studies have 
shown in the lung cancers with mutant PIK3CA, there are 
also mutations at other driver oncogenes, such as EGFR, 
KRAS, BRAF, MEK, and anaplastic lymphoma kinase 
(ALK) [141]. Recent studies in melanoma have indicated 
that some components of the PI3K pathway (PTEN, 
MTOR, IRS4, PIK3R1, PIK3R4, PIK3R5 and NFKB1) 
are co-mutated in 17% of BRAF V600E mutant and 9% 
of NRAS mutant melanomas [5]. An overview of the Ras/
PI3K/PTEN/Akt mTOR pathway and the regulator circuits 
is presented in Figure 4.
There are three classes of PI3K, each with distinct 
substrate specificity and lipid products: I, II, and III [135-
138]. In mammals, class I PI3Ks are the best understood 
PI3Ks and are expressed in all cell types. To date, class I 
PI3Ks are the most widely implicated in human cancers 
[2,14,135-138] and for this reason they will be the only 
PI3Ks discussed in detail in this review. Class I PI3Ks 
are divided further into A and B subtype. Class IA PI3Ks 
are dimers comprising a regulatory (p85-alpha, p85-beta, 
p55-alpha, p55-gamma, p50-alpha) and a catalytic (p110-
alpha, p110-beta, p110-delta) subunit. Class IA PI3Ks act 
downstream of both tyrosine kinase receptors (TKRs) and 
G protein-coupled receptors (GPCRs). The single class 
IB PI3K comprise a p110-gamma catalytic subunit which 
binds one of two related regulatory subunits, p101 and 
p87. Class IB PI3Ks are activated downstream of GPCRs 
[2,14,135-138]. PI3K serves to phosphorylate a series of 
membrane phospholipids including: phosphatidylinositol 
4-phosphate and phosphatidylinositol 4,5-bisphosphate, 
catalyzing the transfer of ATP-derived phosphate to 
the D-3 position of the inositol ring of membrane 
phosphoinositides, thereby forming the second messenger 
lipids phosphatidylinositol 3,4-bisphosphate (PIP2) 
and phosphatidylinositol 3,4,5-trisphosphate (PIP3) 
[2,14,135-138]. Most often, PI3K is activated via the 
binding of a ligand to its cognate receptor, whereby 
p85 associates with phosphorylated Y residues on the 
receptor via a Src-homology 2 (SH2) domain. After 
association with the receptor, the p110 catalytic subunit 
then transfers phosphate groups to the aforementioned 
membrane phospholipids [2,14,135-138].  It is these 
lipids, specifically PIP3, that attract a series of kinases 
to the plasma membrane thereby initiating the signaling 
cascade [2,14,135-138,142]. The p85 PI3K subunit also 
plays key roles in regulating flux through this pathway by 
controlling both PI3K p110 and PTEN [143]. 
Downstream of PI3K is the primary effector 
molecule of the PI3K signaling cascade, Akt/ protein 
kinase B (PKB) which is a 57 kDa S/T kinase that 
phosphorylates many targets on RxRxxS/T (R = Arginine) 
consensus motifs [1-3, 135-138, 142-148]. Driver AKT 
mutations are detected in some human cancer [10,49]. 
Akt was discovered originally as the cellular 
homologue of the transforming retrovirus AKT8. It is a 
kinase with properties similar to protein kinases A and 
C [2,144]. Akt contains an amino-terminal pleckstrin 
homology (PH) domain that serves to target the protein 
to the membrane for activation [1-3,135-138,142-148]. 
Within its central region, Akt has a large kinase domain 
and is flanked on the carboxy-terminus by hydrophobic 
and proline-rich regions. Akt-1 is activated via 
phosphorylation of two residues: T308 and S473, Akt-2 
and Akt-3 are highly related molecules and have similar 
modes of activation. Akt-1 and Akt-2 are ubiquitously 
expressed while Akt-3 exhibits a more restricted tissue 
distribution. Akt-3 is found abundantly in nervous tissue 
[144-148]. 
The phosphotidylinositide-dependent kinases 
(PDKs) are responsible for activation of Akt. PDK1 is 
the kinase responsible for phosphorylation of Akt-1 at 
T308 [144]. Akt-1 is also phosphorylated at S473 by 
the mammalian target of Rapamycin (mTOR) complex 
referred to as (Rapamycin-insensitive companion 
of mTOR/mLST8 complex) mTORC2 [135-138]. 
Before the discovery of the ability of mTORC2 to 
phosphorylate S473, the activity responsible for this 
phosphorylation event was referred to as PDK2. Akt-
2 and Akt-3 are phosphorylated in similar fashions. 
Therefore, phosphorylation of Akt is complicated as it 
is phosphorylated by a complex that lies downstream 
of activated Akt itself [1,2,135-138]. Thus, as with the 
Ras/Raf/MEK/ERK pathway, there are feedback loops 
Oncotarget 2012; 3: 954-987964www.impactjournals.com/oncotarget
that serve to regulate the activity of the Ras/PI3K/
PTEN/Akt/mTOR pathway. These events also serve to 
illustrate that these signal transduction pathways are not 
really linear, but highly interactive. Once activated, Akt 
leaves the cell membrane to phosphorylate intracellular 
substrates. Akt activity is regulated by many mechanisms 
including the levels of PIP3 which are controlled 
positively and negatively by PI3K of PTEN respectively, 
by phosphorylation by PDK1 and mTORC2 as well as 
ubiquitination [149]. 
After activation, Akt is able to translocate to the 
nucleus [1-3, 134-138] where it affects the activity of a 
number of transcriptional regulators. Some examples 
of molecules which regulate gene transcription that are 
phosphorylated by Akt include: CREB [149], E2F [150], 
nuclear factor kappa from B cells (NF-kappaB) via 
inhibitor kappa B protein kinase (I-kappaK) [151], the 
forkhead (FOXO) transcription factors [152], and murine 
double minute 2 (MDM2) which regulates p53 activity [1-
3,134-138]. These are all either direct or indirect substrates 
of Akt and each can regulate cellular proliferation, survival 
and some can modulate EMT (e.g., NF-kappaB) [135,151-
154]. Besides transcription factors, Akt targets a number 
of other molecules to affect the survival state of the cell 
including: the pro-apoptotic molecules Bcl-2-associated 
death promoter (BAD) and Bcl-2 interacting mediator 
of cell death (Bim) [153], as well as, glycogen-synthase 
kinase-3beta (GSK-3beta) (see Figure 3) [164]. GSK-3beta 
regulates beta-catenin protein stability, which is important 
in regulation of EMT. When Akt phosphorylates GSK-
3beta, it is targeted to the proteasome and beta-catenin is 
active and able to stimulate gene expression. Hence the 
PI3K/PTEN/Akt/mTOR pathway is connected to the Wnt/
beta-catenin, p53 and many additional pathways including 
Ras/Raf/MEK/ERK.
Akt has many diverse effects on proliferation, 
survival, senescence, invasion, metastasis, drug resistance 
and DNA damage repair and autophagy [155-162]. Akt 
is involved in cell cycle progression and migration [163]. 
Akt may also affect the ability of miRNAs to target their 
respective genes. Akt is a known inhibitor of autophagy 
and inhibition of Akt by certain tumor suppressors will 
induce autophagy [164]. A recent study suggests that Akt 
may regulate the processing of certain miRNAs by post-
transcriptional mechanisms regulate miRNAs’ processing 
or their stability which induces rapid fluctuation in their 
levels [165]. Akt and its downstream targets (e.g., the Foxo 
transcription factor) are involved in aging and suppression 
of Akt activity, which results in increased Foxo activity, by 
food supplements such as curcumin, prevents aging [166]. 
Negative regulation of the PI3K pathway is 
primarily accomplished through the action of the PTEN 
tumor suppressor protein. PTEN encodes a lipid and 
protein phosphatase whose primary lipid substrate is PIP3 
[1-3,136-138,167-170]. The purported protein substrate(s) 
of PTEN are more varied, including focal adhesion kinase 
(FAK), the Shc exchange protein and the transcriptional 
regulators ETS-2 and Sp1 and the platelet-derived growth 
factor receptor (PDGFR) [167-171]. Both the lipid and 
protein phosphatase activities of PTEN are important for 
prevention of invasion [171].
PTEN has four primary structural domains. In 
the amino terminus is the lipid and protein phosphatase 
domain. This is adjacent to the C2 domain that is 
responsible for lipid binding and membrane localization. 
Next are two protein sequences rich in proline (P), 
glutamic acid (E), S, and T (PEST) domains that regulate 
protein stability.  Lastly, PTEN has a PDZ domain [PDZ 
is an abbreviation for the first three proteins identified to 
share this domain which are post synaptic density protein 
95 (PSD95), Drosophila disc large tumor suppressor 
(Dlg1), and zonula occludens-1 protein (zo-1)], which 
helps facilitate protein-protein interactions. Mutations 
within the phosphatase domain have been reported to 
nullify the endogenous function of PTEN [1,3,167]. Thus 
PTEN is an enticing therapeutic target for activation since 
it is frequently inactivated in many human cancers through 
point mutations as well as other genetic and biochemical 
mechanisms [e.g., promoter hypermethylation, gene 
deletion, expression of various interacting proteins, 
miRNAs, phosphorylation, acetylation, ubiquitination, 
oxidization and others]. PTEN inactivation results in 
elevated Akt activity and abnormal growth regulation 
[1,3,167,172]. Thus, drugs reactivating PTEN could 
potentially be useful in the therapy of some types of 
tumors driven by PTEN inactivation.
Another negative regulator of the PI3K pathway is 
the PH domain leucine-rich repeat protein phosphatase 
(PHLPP). PHLPP is a tumor suppressor gene. PHLPP 
dephosphorylates S473 on Akt-1 which can induce 
apoptosis and inhibits tumor growth [173]. Two 
other phosphatases, SHIP-1 and SHIP-2, remove the 
5-phosphate from PIP3 to produce PIP2 [174-177]. SHIP1 
and SHIP2 are tumor suppressor genes. Mutations in these 
phosphatases, which eliminate their activity, can lead to 
tumor progression. 
Next we discuss some of the key targets of Akt 
that can also contribute to abnormal cellular growth and 
are key therapeutic targets [1-3,135-138,178-185]. Akt-
mediated regulation of mTOR activity is a complex, 
multi-step phenomenon.  Akt inhibits tuberous sclerosis 2 
(TSC2 or tuberin) function through direct phosphorylation 
[179]. TSC2 is a GAP that functions in association with 
TSC1 to inactivate the small G protein Ras homolog 
enriched in brain (Rheb) [180-182]. TSC1 and TSC2 are 
both tumor suppressor and gatekeeper genes [186,187]. 
TSC2 has been recently shown to have other roles, for 
example when it interacts with transforming acidic coiled-
coil-3 (TACC3) a centromere binding protein, it maintains 
nuclear membrane structure and regulates cell division. 
[188]. 
TSC2 phosphorylation by Akt represses GAP 
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activity of the TSC1/TSC2 complex, allowing Rheb 
to accumulate in a GTP-bound state. Rheb-GTP then 
activates, through a mechanism not yet fully elucidated, 
the protein kinase activity of mTOR which complexes with 
Raptor (Regulatory associated protein of mTOR) adaptor 
protein, DEP domain containing mTOR-interacting 
protein (DEPTOR) and mLST8, a member of the Lethal-
with-Sec-Thirteen gene family, first identified in yeast, 
FK506 Binding Protein 38 (FKBP38) and proline-rich Akt 
substrate 40 kDa protein (PRAS40) [134-138]. Raptor has 
also recently been shown to have other roles, including 
interactions with the rDNA transcriptional apparatus in the 
nucleoli [189].
mTORC1 inhibits Akt via a negative feedback loop 
which involves, at least in part, p70S6K [181]. This is due 
to the negative effects that p70S6K has on IRS-1 [134-
138]. p70S6K phosphorylates IRS-1 on S312 and/or S636/
S639. This targets IRS-1 to the proteasome where it is 
degraded. Hence PI3K/Akt signaling downstream of IRS-
1 is downregulated when p70S6K is active. Rapamycin 
treatment blocks mTORC1 and p70S6K activation, thus 
this loop is broken and Akt is activated.  
Deptor is another component of the mTORC1 
complex. DEPTOR may be a tumor suppressor gene as 
decreased expression of DEPTOR results in increased 
mTORC1 activity [190]. 
The mechanism(s) by which Rheb-GTP activates 
mTORC1 have not been fully elucidated, however it 
requires Rheb farnesylation and can be blocked by 
farnesyl transferase (FT) inhibitors. It has been proposed 
that Rheb-GTP would relieve the inhibitory function of 
FKBP38 on mTOR, thus leading to mTORC1 activation 
[182]. 
As stated previously, TSC1 and TSC2 have 
important roles in the regulation of mTORC1. An 
additional molecule important in this regulation is the 
liver kinase B (LKB1 also known as STK11). LKB1 is an 
important tumor suppressor and gatekeeper mutations of 
LKB1 cause the rare Peutz-Jeghers Syndrome (PJS) which 
is a cancer-prone syndrome [191]. LKB1 is a gatekeeper 
gene and mutations in LKB1 are involved in the formation 
of hamartomatous polyps in PJS patients. LKB1 is an 
upstream activator of 5’AMP-activated protein kinase 
(AMPK) which activates TSC2 that negatively regulates 
mTORC1 [192,193]. LKB1 is a critical regulator of cell 
polarity and energy/metabolism control and exerts it vast 
effects via diverse effectors [138,194,195]. 
AMPK is considered a metabolic gatekeeper 
important in many diseases including diabetes, cancer 
and neurologic disorders [196-203]. AMPK is activated 
by the diabetes drug metformin [193]. Hence metformin 
will indirectly suppress mTORC1 activity. Chronic 
overfeeding increases mTORC1 activity which in turn 
promotes adiposity and decreases lifespan and is also 
believe to enhance cancer growth [204,205]. Inhibiting 
mTORC1 activity by drugs such as metformin and other 
drugs (including rapamycin) may not only aid in the 
treatment of diabetics, but also improve cancer therapies 
and increase longevity [206-216]. 
 Akt also phosphorylates PRAS40, an inhibitor 
of mTORC1, and by doing so, it prevents the ability 
of PRAS40 to suppress mTORC1 signalling (recently 
reviewed in [135-138]). Thus, this could be yet another 
mechanism by which Akt activates mTORC1. Moreover, 
PRAS40 is a substrate of mTORC1 itself, and mTORC1-
mediated phosphorylation of PRAS40 prevents inhibition 
of additional mTORC1 signaling [135-138,181]. Due to 
its negative regulation of mTORC1, PRAS40 has been 
proposed to have gatekeeper anti-apoptotic functions 
[217]. Also Ras/Raf/MEK/ERK signaling positively 
impinges on mTORC1. Both p90Rsk-1 and ERK 1/2 
phosphorylate TSC2, thus suppressing its inhibitory 
function [135-138,181]. Moreover, mTORC1 inhibition 
resulted in ERK 1/2 activation, through p70S6K/PI3K/
Ras/Raf/MEK [183].
The relationship between Akt and mTOR is further 
complicated by the existence of the mTOR/Rictor 
complex (mTORC2), which, in some cell types, displays 
rapamycin-insensitive activity. mTORC2 is comprised 
of rapamycin insensitive companion of mTOR (Rictor), 
mTOR, DEPTOR, mLST8, Stress activated protein kinase 
INteracting protein 1 (SIN1) and protein observed with 
Rictor (Protor). mTORC2 phosphorylates Akt on S473 
in vitro which facilitates T308 phosphorylation [185]. 
Thus, mTORC2 can function as the elusive PDK-2 which 
phosphorylates Akt-1 on S473 in response to growth 
factor stimulation [186,218]. Akt and mTOR are linked 
to each other via positive and negative regulatory circuits, 
which restrain their simultaneous hyperactivation through 
mechanisms involving p70S6K and PI3K [135-138,181]. 
Assuming that equilibrium exists between these two 
complexes, when the mTORC1 complex is formed, it 
could antagonize the formation of the mTORC2 complex 
and reduce Akt activity [180,181]. Thus, at least in 
principle, inhibition of the mTORC1 complex could result 
in Akt hyperactivation. This is one problem associated 
with therapeutic approaches using rapamycin or modified 
rapamycins (rapalogs) that block some, but not all, actions 
of mTOR.
mTOR is a 289-kDa S/T kinase. mTOR was the 
first identified member of the phosphatidylinositol 
3-kinase-related kinase (PIKK) family [135-138,219]. 
Recently mTOR has been shown to be cell cycle regulated 
[220,221]. mTOR has been referred to as the gatekeeper 
of autophagy. mTOR plays important roles in many 
biological processes, including; energy control [222-224], 
insulin resistance [225], diabetes [226], seizures [227,228], 
protein homeostasis [229], regulation of tRNA expression 
[230,231], cell cycle arrest [232], cell differentiation 
[233,234], cell migration [235,236], follicle development 
[237], DNA damage checkpoint [238], cellular quiescence/
senescence [239-248], cancer [249,250], aging [251-260] 
Oncotarget 2012; 3: 954-987966www.impactjournals.com/oncotarget
and Parkinson’s disease [261]. 
mTORC1 is a repressor of autophagy, a lysosome-
dependent degradation pathway which allows cells to 
recycle damaged or superfluous cytoplasmic content, 
such as lipids, proteins, and organelles [262-280]. As a 
consequence, cells produce metabolic precursors for 
macromolecular biosynthesis or ATP generation. In cancer 
cells, autophagy fulfills a dual role, as it has both tumor-
promoting and tumor-suppressing properties. Functional 
autophagy prevents necrosis and inflammation, which 
can lead to genetic instability. However, autophagy might 
be important for tumor progression by providing energy 
through its recycling mechanism during unfavorable 
metabolic circumstances, which are very common in 
tumors [262-280]. 
A model has been proposed by Dr. Michael P. 
Lisanti and colleagues which is called the reverse 
Warburg Effect. This model proposes that the aerobic 
glycolysis occurring in the tumor associated fibroblasts 
and not in the actual epithelial tumor cells [266,270-274]. 
This results in the transfer of high-energy metabolites 
(lactate and pyruvate) to adjacent epithelial cancer cells 
which fuel the cancer cells allowing them to invade and 
metastize. In addition, oxidative stress generated by the 
cancer cells induces autophagy of the tumor associated 
fibroblasts which the cancer cells then recycle and use 
to fuel their growth. Anti-oxidants (N-acetyl cysteine, 
NAC), quercetin and the anti-diabetes drug metformin) 
or autophagy inhibitors (chloroquine) will suppress 
the destruction of caveolin-1 in stromal fibroblasts and 
inhibit cancer growth. Caveolin-1 is a key protein at the 
cell membrane which serves to organize other important 
signaling molecules into signaling complexes (e.g., Fak, 
Src). Decreased expression of caveolin-1 is associated 
with a poorer prognosis of breast and other cancers.
 Autophagy is also important in hematopoietic 
cancer [275-277]. Autophagy can be regulated by 
epigenetic mechanisms [278].  Autophagy may also 
become defective in certain drug resistant cells [279]. 
Defective autophagy may be controlled by the p53 rheostat 
in cancer [280]. Clearly autophagy is a very important 
survival process which is regulated in part by mTORC1.
mTOR regulates translation in response to nutrients 
and growth factors by phosphorylating components of 
the protein synthesis machinery, including p70S6K and 
eukaryotic initiation factor (eIF)-4E binding protein-1 
(4EBP-1), the latter resulting in release eIF-4E, allowing 
eIF-4E to participate in the assembly of a translational 
initiation complex [1-3,135-138]. p70S6K phosphorylates 
the 40S ribosomal protein S6, (rpS6), leading to translation 
of “weak” mRNAs [1-3,135-138]. Integration of a variety 
of signals (mitogens, growth factors, hormones) by mTOR 
assures cell cycle entry only if nutrients and energy are 
sufficient for cell duplication [1-3,135-138]. 
Unphosphorylated 4E-BP1 interacts with the cap-
binding protein eIF4E and prevents the formation of the 
4F translational initiation complex (eIF4F); by competing 
for the binding of eukaryotic initiation factor 4G (eIF4G) 
to eIF4E. 4E-BP1 phosphorylation by mTORC1 results in 
the release of the eIF4E, which then associates with eIF4G 
to stimulate translation initiation [1-3,135-138]. 
eIF4E is a key component for translation of 5’ 
capped mRNAs, that include transcripts encoding 
proliferation and survival promoting proteins, such as 
c-Myc, cyclin D1, cyclin-dependent kinase-2 (CDK-2), 
signal activator and transducer of transcription-3 (STAT-
3), ornithine decarboxylase, survivin, B-cell lymphoma 
2 (Bcl) -2, Bcl-xL, myeloid cell leukemia-1 (Mcl-1) and 
others [1-3,135-138].
The mechanisms which control mTORC2 activity 
have only begun to be revealed. mTORC2 activation 
requires PI3K, as inhibition of PI3K decreases mTORC2 
activity [138]. mTORC2 phosphorylates Akt-1 on S473 
that enhances subsequent Akt phosphorylation on T308 
by PDK1. mTORC2 phosphorylates other members of 
the family of protein kinase A, G, and C (AGC) including 
as serum/glucocorticoid-regulated kinase (SGK1) [281]. 
mTORC2 has been shown to phosphorylate certain 
protein kinase C (PKC) family members [282]. mTORC2 
has important roles in regulation of cell growth and it is 
a critical biological sensor [283]. For mTORC2 activity, 
it requires association with the ribosome and this may 
a critical sensor promoting growth when conditions 
are favorable but hindering growth when conditions 
are not favorable [284-287]. mTORC2 influences actin 
cytoskeletal organization [288]. Along these same lines, 
mTORC2 has been implicated in various aspects of tumor 
progression including motility, invasion and metastasis 
[289]. 
PI3K, Akt, and mTORC1/2 are linked to each 
other via regulatory feedback loops, which restrain their 
simultaneous hyperactivation. Negative regulation of Akt 
activity by mTORC1 is dependent on p70S6K-mediated 
phosphorylation of IRS-1/2 adapter proteins, downstream 
of the IR and/or IGF-1R [290-292]. IRS-1 and IRS-2 
are normally required to activate class IA PI3Ks after 
stimulation of IR and IGF-1R tyrosine kinase activity. 
When mTORC1 is active, p70S6K phosphorylates the 
IRS-1/2 proteins on serine residues, targeting them for 
proteasomal degradation [293,294].
Inhibition of mTORC1 signaling by rapamycin/
rapalogs removes the previously mentioned negative 
feedback loop and activates Akt through PI3K. Inhibiting 
mTORC1 with rapamycin will in some situations activate 
mTORC2.  Recent findings have also highlighted the 
existence of a rapamycin-sensitive, mTORC1/p70S6K-
mediated phosphorylation of Rictor on T1135. This 
phosphorylation event exerted a negative regulatory effect 
on the mTORC2-dependent phosphorylation of Akt in vivo 
[295]. Thus, both mTORC1 and mTORC2 could control 
Akt activation. PI3K/Akt/mTOR signaling is tightly 
controlled and negatively regulated by several lipid and 
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protein phosphatases. PTEN removes the 3’-phosphate 
from PIP3, thereby antagonizing network signalling 
[296,297].  Two other lipid phosphatases, SHIP-1 and -2, 
remove the 5-phosphate from PIP3 to yield PIP2 [298]. 
PP2A downregulates Akt activity directly, by 
dephosphorylating it at T308 and accumulating evidence 
indicates that PP2A acts as a tumor suppressor [299]. 
PP2A is an essential phosphatase critically involved 
in regulation of cell cycle progression [300] and DNA 
damage response [301] as well as p53 stability and other 
important biochemical events. 
 Recent findings have indicated that there exists an 
inverse relationship between the levels of the B55-alpha 
regulatory subunit of the PP2A phosphatase, that functions 
as an Akt phosphatase [302] and the levels of T308 (but 
not S473) Akt phosphorylation levels in AML blast cells 
[303]. This finding suggested that B55-alpha is mediating 
dephosphorylation of Akt at T308, but not S473, in 
AML cells [303]. Interestingly, this study reported lower 
levels of the PP2A B55-alpha regulatory subunit in AML 
primary cells when compared with CD34+ bone marrow 
cells from healthy donors. Another report has documented 
that PP2A activity downregulation is a recurrent event in 
AML patients [304]. Moreover, the phosphorylated S473 
residue on Akt is dephosphorylated by the two isoforms 
of PHLPP (1 and 2) Decreased PHLPP activity has been 
linked to specific types of cancers [305,306].
mTOR also controls the translation of hypoxia-
inducible transcription factor-1-alpha (HIF-1-alpha) 
mRNA [2,26,135-138,307]. HIF-1-alpha upregulation 
leads to increased expression of angiogenic factors 
such as VEGF and PDGF which are important in 
many physiological processes including, blood supply, 
cancer and diabetes [26,308-310]. Moreover, HIF-1-
alpha regulates the glycolytic pathway by controlling 
the expression of glucose-sensing molecules including 
glucose transporter (Glut) 1 and Glut3 [311,312]. p70S6K 
and 4E-BP1 also control cell growth and hypertrophy by 
regulating protein synthesis. Hence targeting the mTOR 
pathway could have many effects on the regulation of 
cellular growth. 
Mutations or Altered Expression of the Ras/PI3K/
PTEN/Akt/mTOR Pathways Can Alter Sensitivity 
to Therapy
 Mutations resulting in activation of the Ras/
PI3K/PTEN/Akt/mTOR pathways and play critical 
roles in EMT, tumor progression and aging [313-319]. 
Mutations/gene amplification of RAS, PIK3CA, PIK3R1, 
PIK3R4, PIK3R5, IRS4, PTEN, AKT1, TSC1, TSC2, 
RHEB, MTOR, and 70S6K are detected in certain cancers 
[5,320]. Aberrant activation of this pathway may be a 
contributing factor to transformation of diverse types of 
cancers [321].  PIK3CA is mutated in approximately 25% 
of breast, 32% of colorectal, 30% of endometrial, 27% 
of brain, 25% of gastric, 4% of lung cancers [322-326]. 
These mutations are clustered in small hot-spot regions 
within the helical (E542, E545) and kinase (H1047) 
domains [322-326]. The locations of these mutations have 
been recently critically evaluated [326]. These mutations 
frequently result in activation of its kinase activity [326]. 
Furthermore increased expression of the Ras/PI3K/Akt/
mTOR pathway also occurs frequently in some cancers 
as the PIKC3A gene is amplified in approximately 40% of 
ovarian cancers [325].
Activation of PI3K/PTEN/Akt/mTOR signaling 
through mutation, inactivation or silencing of pathway 
components occurs in various malignancies, including 
liver cancer [327]. Deregulation of this pathway has 
clinical importance in hepatocellular carcinoma (HCC). 
For example, data from genomic sequence of HCC 
samples identified mutations in PIK3CA in 50% of patients 
with poor prognosis, survival length < 3 years following 
partial liver resection, and only 10% of the HCC patients 
with a good prognosis had mutations in PIK3CA [327]. 
The identified mutations were restricted to residues H1047 
in 61.1%, to E545 in 33.3%, and to E542 in 5.5% of cases, 
and as a consequence this result in gain of enzymatic 
function and consequently in oncogenic activity of PI3K 
[327]. 
Mutations at PTEN in Human Cancer
 Germline PTEN mutations are present in 
approximately 80% of patients with Cowden syndrome 
[328]. This disease, which is also known as multiple 
hamartoma syndrome, is a familial syndrome that includes 
diverse types of cancer conditions including early onset 
breast cancer. Mutations have been reported to occur at 
PTEN in breast cancer in varying frequencies (5-21%) 
[329,330]. Loss of heterozygosity (LOH) is probably 
more common (30%) [330]. Mutations at certain residues 
of PTEN, that are associated with Cowden’s disease, 
affect the ubiquitination of PTEN and prevent nuclear 
translocation. These mutations leave the phosphatase 
activity intact [331]. Inhibition of PTEN activity leads to 
centromere breakage and chromosome instability [332]. 
Thus PTEN has diverse activities. 
Akt and mTOR phosphorylation are frequently 
detected in ovarian and endometrial cancers. An early 
occurrence in endometrial cancer is the loss of functional 
PTEN activity by mutation or other mechanisms, this 
occurs in approximately 40-80% of patients [333]. Since 
the loss of PTEN results in activation of Akt, that in turn 
up-regulates mTOR activity, cancer cells deficient in 
PTEN are thought to be major targets of mTOR inhibitors.
Alterations in PTEN expression have also been 
implicated in HCC. The best evidence that strongly 
supports the connection between PTEN-suppression and 
liver carcinogenesis comes from genetic studies. All mice 
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with PTEN-deficient hepatocytes exhibited liver adenomas 
and 66% of them developed HCC [334]. In these mice, 
hepatocytes were hyperproliferative and displayed an 
abnormal activation of Akt [334]. Furthermore, although 
mutations in the PTEN gene rarely occur in HCC, frequent 
loss of heterozygosity of PTEN allele has been identified 
in 20-30% of HCC patients [335-338]. In addition, down-
regulation of PTEN expression may be partly due to PTEN 
promoter methylation [339]. PTEN expression plays a 
critical role in HCC progression and patient’s outcome. 
Patients with high expression of PTEN had a significantly 
better overall survival than patients with low PTEN 
expression [340]. Hepatitis viruses protect hepatocytes 
from apoptotic cell death by promoting the activation 
of Ras/PI3K/Akt/mTOR survival pathway [341,342]. 
Among the four proteins encoded by HBV genome, HBx 
has been reported to be involved in hepatocarcinogenesis. 
It has been reported that HBx expression downregulated 
PTEN expression in hepatocytes [342]. In contrast, PTEN 
expression in liver cells downregulated HBx-induced 
PI3K and Akt activities [343]. Therefore, these studies 
suggest the possible use of PTEN as a target in therapeutic 
approaches for the treatment of at least those HCC caused 
by HBV infection.
Mutations and hemizygous deletions of PTEN have 
been detected in AML and non Hodgkin’s lymphoma 
(NHL) and other cancers [344,345]. Although many 
groups have investigated the PTEN-phosphorylation status 
in leukemia and lymphoma, its relevance concerning 
Akt-activation is still not clear [344-348]. PTEN 
phosphorylation as well as low or absent PTEN expression 
has been observed in AML.
The level of PTEN expression does not always 
correlate with the degree of phosphorylation of Akt [344]. 
Although the picture concerning PTEN-inactivation 
and corresponding Akt-activation is not clear, in vivo 
studies indicate, that PTEN dysregulation promotes 
leukemogenesis. PTEN-deficient hematopoietic stem 
cells display dysregulated cell cycle progression, and the 
mice develop a myeloproliferative disease which leads to 
leukemic transformation [346]. In T-acute lymphoblastic 
leukemia (T-ALL), PTEN-downregulation is also closely 
correlated with Akt-activation [347,348]. To discern 
the role of PTEN for Akt-activation, it may be useful to 
exclude concomitant causes for Akt-activation such as 
mutant upstream targets and to include the investigation 
of regulators of PTEN such as c-Myc and Notch/Hes1 
[347,348].
PTEN promoter methylation leads to low PTEN 
expression [349]. In one study, 26% of primary breast 
cancers had low PTEN levels that correlated with lymph 
node metastases and poor prognoses [350]. 
Other mechanisms important in the regulation of 
PTEN are miRNAs. Certain miRNAs have been shown 
to regulate PTEN protein expression. mi-214 induces 
cell survival and may contribute to oncogenesis and drug 
resistance (see below) by binding the 3’untranslated 
region (3’UTR) of PTEN which prevents PTEN mRNA 
translation and leads of overexpression of downstream Akt 
[351].
In some cancer settings, PTEN and BRAF mutations 
appear to interact. Two studies papers have highlighted 
the hypothesis of mutant BRAF- and PTEN-loss-driven 
carcinogenesis in mouse models [352,353]. In a study by 
Dhomen et al., inducible expression of B-RafV600E was 
sufficient to induce multiple melanocytic lesions including 
skin hyperpigmentation, dysplastic nevi and melanoma 
[352]. Tumor cells from these B-RafV600E mice displayed 
both melanoma growth and melanocyte senescence in 
this system. Approximately 70% of these mice developed 
melanomas that exhibited histological and molecular 
characteristics similar to that of human melanoma and 
were able to colonize the lungs in nude mice [352]. In 
contrast, another group of researchers generated mice 
that conditionally-expressed melanocyte-specific BRAF 
V600E that were only able to induce benign melanocytic 
hyperplasias and were unable to progress any further over 
a 15-20 month period [353].  However, BRAF V600E 
expression in a PTEN gene-silenced background led to 
the production of melanomas with 100% establishment, 
short latency and metastasis to lymph nodes and lungs. 
This development was prevented by the treatment of mice 
with either the mTOR inhibitor rapamycin or the MEK1/2 
inhibitor (PD0325901). Moreover, while combination 
treatment with rapamycin or PD0325901 led to the 
reduction of established tumors, upon termination of drug 
treatment the melanomas reappeared most likely due to 
the presence of drug resistant melanoma-initiating cells 
in these mice. Overall, these two papers further validated 
the mutated B-Raf/MEK/ERK and the PI3K/Akt/mTOR 
pathways, as promising therapeutic targets in melanoma.
Mutations at SHIP Phosphatase in Human 
Cancer 
The SHIP-1 phosphatase has been implicated as a 
suppressor of hematopoietic transformation as it basically 
can prevent Akt-activation [354]. SHIP-1-deficient 
mice develop a myeloproliferative disease [355] and an 
inactivating point mutation (SHIP1 V684E) has been 
observed in approximately one of thirty AML cases [354]. 
Also another mutation, SHIP1 Q1154L, has been observed 
in AML, but was even less frequent (1 of 192 cases) [355]. 
Though some studies confirmed, that SHIP-1 is a leukemia 
suppressor [354,355] it is unlikely that SHIP1 mutations 
are a frequent cause of Akt-activation in AML. Disruption 
of PTEN or SHIP activity by various genetic mechanisms 
could have vast effects on different processes affecting 
the sensitivity of different cancers to various therapeutic 
approaches.
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Mutations of AKT in Human Cancer
The roles that Akt plays in cancer are complex. 
Akt can be activated by genetic mutations, genome 
amplifications and more commonly by mutations in 
upstream signaling components. Amplification of Akt-
2 was observed in human ovarian carcinomas [356]. 
Increased levels of Akt are detected in carcinomas of 
the breast, ovary and prostate and are associated with a 
poorer prognosis in comparison with tumors that do not 
display increased levels of expression. AKT is a multi-
gene family that consists of AKT1, AKT2 and AKT3. 
AKT1 has been reported to be mutated in some breast, 
colorectal, melanoma and ovarian cancers [357-359] (see 
below). AKT2 is not mutated frequently in human cancer. 
AKT2 is amplified in certain cancers (e.g., 12.1% ovarian 
and 2.8% breast carcinomas) [359]. Mutation of AKT3 has 
been detected in some melanoma samples [360]. 
AKT1 is mutated in 2 to 8% of breast, 6% of 
colorectal and 2% of ovarian cancers samples examined in 
one study [357]. This study documented an Akt mutation 
that results in an E for a lysine (K) substitution at amino 
acid 17 (E17K) in the PH domain. Cells with this AKT1 
mutation have not been observed to have mutations at 
PIK3CA; a similar scenario is also frequently observed 
with RAS and BRAF mutations [361]. This AKT1 mutation 
alters the electrostatic interactions of Akt-1 which allows it 
to form new hydrogen bonds with the natural PIP3 ligand 
[357]. The PH domain mutation confers many different 
properties to the AKT1 gene. Namely the mutant AKT1 
gene has: 1) an altered PH domain conformation, 2) is 
constitutively-active, 3) has an altered cellular distribution 
as it is constitutively-associated with the cell membrane, 
4) morphologically transforms Rat-1 tissue culture cells 
and 5) interacts with c-Myc to induce leukemia in E-mu-
Myc mice (E-mu = Enhancer of immunoglobulin mu 
gene, Myc = Myc oncogene originally isolated in avian 
myelocytomatosis virus) [357]. This PH domain mutated 
AKT1 gene does not alter its sensitivity to ATP competitive 
inhibitors, but does alter its sensitivity to allosteric kinase 
inhibitors [357]. These results demonstrate that targeting 
the kinase domain of Akt may not be sufficient to suppress 
the activity of various AKT genes that have mutations in 
the PH domain.  AKT1 and AKT3 E17K mutations in lung 
cancer have been reported to be rare [362]. 
Alterations of Akt Expression in Human Cancer
Akt is often upregulated in cancer cells and its 
overexpression is associated with a poor prognosis. 
Increased expression of Akt can result from activating 
PIK3CA mutations, elimination or decrease in PTEN 
activity or elevated PKC-epsilon expression. Elevated Akt 
expression has also been associated with the pathology of 
pancreatic, glioma and prostate cancers [363-368]. 
Pancreatic cancer cells have elevated IGF-1R 
expression and it is well known that Akt regulates IGF-
1R expression [369]. This Akt effect on IGF-1R has 
been suggested to be responsible for the invasiveness 
of pancreatic cancer cells.  Active Src can also activate 
Akt, and both Src and Akt up-regulate IGF-1R expression 
in this cancer. It has been demonstrated that IGF-I is 
expressed in the surrounding stromal cells but not in 
the cancer cells. This IGF-1 expression may serve as a 
paracrine growth factor to activate the IGF-1R pathway 
and the downstream Ras/PI3K/Akt/mTOR pathway in 
pancreatic cells. 
Cyclooxygenase-2 (COX-2) is expressed at 
high levels in some primary endometrial tumors and 
is associated with an aggressive phenotype [370]. Akt 
is elevated and PTEN is often mutated in these cancers 
which can result in Akt activation.  NF-kappaB activation 
has been shown to have oncogenic effects important in 
the control of apoptosis, cell cycle, differentiation, cell 
migration and inflammation [371-383]. Akt may exert 
its effects through the NF-kappaB pathway and COX-
2 is the regulator of this pathway.  Akt regulates COX2 
gene and protein expression in endometrial cancers. This 
study was undertaken to examine the involvement of 
Akt in the regulation of NF- kappaB and COX-2 [370]. 
The expression of both I-kappaB and phosphorylated 
I-kappaB were increased in the cells containing mutant 
PTEN genes.  In contrast, there was no difference in NF-
kappaB protein abundance between the cell lines, which 
differed in PTEN gene status. I-kappaB phosphorylation 
by the PI3K pathway was inhibited by the PI3K inhibitors 
Wortmannin and LY294002. There was less NF-kappaB 
nuclear activity, less COX-2 expression and more 
apoptosis after inhibition of the PI3K pathway. Dominant 
negative (DN) Akt blocked I-kappaB phosphorylation and 
decreased COX-2 expression. In contrast, introduction 
of constitutively-active Akt induced I-kappaB 
phosphorylation and up-regulated COX-2 expression.
When PTEN is mutated, Akt signals via the NF-
kappaB/I-kappaB pathway to induce COX-2 expression 
in endometrial cancer cells. COX-2 can inhibit apoptosis, 
increase angiogenesis, and promote invasiveness. COX-
2 also promotes inflammation/immunosuppression and 
conversion of procarcinogens into carcinogens that 
contribute to tumorigenesis and a malignant phenotype. 
This study demonstrated that Akt signals via the NF-
kappaB/I-kappaB pathway to induce COX2 gene and 
protein expression in endometrial cancer [370].
Elevated Akt activity can also result in increased 
phosphorylation of mTOR. mTOR was found to be 
phosphorylated in AML blasts, along with its two 
downstream substrates, p70S6K and 4EBP-1, in a PI3K/
Akt-dependent fashion [384]. Nevertheless, others 
failed to detect any relationship between PI3K/Akt 
signalling upregulation and p70S6K phosphorylation in 
AML primary cells [385]. This might occur via the Ras/
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Raf/MEK/ERK pathway activating mTOR via ERK 
phosphorylation [385]. The Ras/Raf/MEK/ERK pathway 
is frequently activated in AML [386-388]. 
Akt is activated in HCC, which results in enhanced 
resistance to apoptosis through multiple mechanisms 
[389-392]. As an example, activation of the Akt pathway 
suppresses transforming growth factor-beta (TGF-
beta) induced apoptosis and growth-inhibitory activity 
of CCAAT/enhancer binding protein alpha (CEBP-
alpha). Activation of Akt is a risk factor for early disease 
recurrence and poor prognosis in patients with HCC [390]. 
Several mechanisms may be responsible for the activation 
of Akt. The high frequency of PIK3CA mutations and/or 
its upregulation in patients with shorter survival might be 
responsible for the Akt hyperactivation found in HCC with 
poor prognosis [335-341]. Selective epigenetic silencing 
of multiple inhibitors of the Ras pathway seems also to be 
responsible for the activation of Akt found in HCC [327]. 
Moreover, impaired expression of PTEN is involved in 
the regulation of Akt activity. Activation of Akt signaling 
and reduced expression of PTEN has been reported in 
40%–60% of human HCC cases [327,335-341]. Some 
well known risk factors, HBV and HCV seem to utilize 
the Ras/PI3K/PTEN/Akt/mTOR pathway for the control 
of hepatocytes survival and viral replication [391,392]. 
Taken together, these data suggest that Ras/PI3K/Akt/
mTOR pathway may represent an important therapeutic 
target for the treatment of HCC among patients with 
differing etiologies that lead to the development of this 
aggressive tumor.
Increased Akt activity due to upstream mutations 
in growth factor receptor genes or PIK3CA or PTEN 
may actually render cells and patients sensitive to Akt 
as well as downstream mTOR inhibitors. The formation 
of the rapamycin-sensitive mTORC1 complex in certain 
cancer cells that overexpress activated Akt may be altered 
in comparison to cells that do not overexpress Akt. In 
cells that express activated Akt, Akt may phosphorylate 
TSC2 resulting in its inactivation. In the presence of 
Akt activation, the mTORC1 complex is formed and 
downstream p70S6K and 4E-BP1 are phosphorylated, 
allowing the dissociation of eIF-4E, ribosome biogenesis 
and protein synthesis. In contrast, in the absence of Akt 
activation, this complex should not be formed. Rapamycin 
targets this complex; hence the cells that express elevated 
levels of activated Akt cells may be more sensitive to 
rapamycin than the cancer cells that do not express high 
levels of activated Akt. In the cells that do not express 
elevated levels of activated Akt, this complex should 
be transiently assembled after growth factor treatment. 
In contrast, the assembly of the rapamycin-insensitive 
mTORC2 complex should be lower in the cells that 
express elevated levels activated Akt than in those cells 
that do not as there is equilibrium between the mTORC1 
and mTORC2 complexes. The significance of these 
complex biochemical signaling events is that cancer 
cells that overexpress activated Akt or lack PTEN/TSC1/
TSC2 expression have an Achilles heel with regards to 
therapeutic intervention as they are highly sensitive to 
rapamycin treatment. 
Mutations of TSC1/TSC2 Genes in Human Cancer
Mutations in the tumor suppressor genes TSC1 and 
TSC2 are associated with a dominant genetic disorder, 
tuberous sclerosis [393,394]. Patients with mutant TSC 
genes develop benign tumors (hamartomas). In contrast 
to Cowden’s patients who have germline mutations 
at PTEN where the patients have a high propensity to 
develop multiple malignancies, TSC patients rarely 
develop multiple malignant cancers, and if they do 
develop malignant cancers they are usually either RCCs 
or angiomyolipomas [394]. This has been hypothesized 
to result from a lack of activation of Akt in cells that have 
mutant TSC1 or TSC2 as mTOR activity is expressed at 
higher levels which results in inhibition of Akt, perhaps 
via the effects of p70S6K on IRS1. TSC1 has been 
shown to be mutated in approximately 15% of urethelial 
carcinomas (bladder cancers) [394]. RCCs are very 
sensitive to rapamycin and rapalogs.
Altered Expression of Components Downstream 
of mTOR in Human Cancer
 mTOR regulates translation by phosphorylating 
components of the protein synthesis machinery, 
including p70S6K and 4E-BP1 [395, 396]. p70S6K 
phosphorylates the 40S ribosomal protein, rpS6, leading 
to active translation of mRNAs [1-3]. In contrast, 4E-
BP1 phosphorylation by mTORC1 on several amino 
acidic residues (S37; T46; S65; T70) results in the 
release of the eIF4E [2]. mRNAs differ in their ability 
to be translated; the length and sequence of the 5’ UTR 
largely dictates the efficiency with which an mRNA 
transcript will be translated. Most mRNAs contain 
short, unstructured GC-poor 5’ UTRs and are efficiently 
translated. In contrast, long, GC-rich sequences in the 5’ 
UTR often hinder the ability of the eIF-4E complex to 
efficiently scan and initiate translation at the start codon. 
These are called weak mRNAs as previously discussed. 
Consequently, under normal circumstances these mRNAs 
are not efficiently translated. However, upon Akt-mediated 
activation of mTOR, these latter mRNAs are highly and 
disproportionately translated. Interestingly, many of these 
weak mRNAs molecules encode oncogenic proteins 
involved in cell proliferation or survival (e.g., c-Myc, 
Mcl-1, cyclin-D, VEGF and survivin). These oncogenic 
mRNAs are therefore tightly regulated at the translation 
level and their accumulation in cancer cells strongly 
contributes to the malignant phenotype. These proteins are 
often subject to the phenomenon of “oncogenic shock” so 
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when an oncogene-addicted cell is treated with a specific 
inhibitor the expression of these proteins rapidly decays.
Several key proteins are overexpressed as a 
consequence of mTOR activation including: c-Myc [397-
399], cyclin D1 [399], and VEGF [400] and others. Cyclin 
D1 has been reported to be overexpressed in prostate 
cancer xenografts and metastases [401], while early stage 
prostatic lesions possess much lower levels of the protein 
[402]. A number of reports support the notion that mTOR 
signaling is a prominent feature of cancer progression and 
aging, as recurrent tumors have altered expression of a 
number of molecular targets of rapamycin including the 
above mentioned genes which encode “weak” mRNAs 
[403-406].  Hence mTOR inhibitors such as rapamycin 
may be effective in cancer therapy.
One central molecule involved in cell growth is 
p70S6K which is regulated by both the Ras/PI3K/PTEN/
Akt/mTOR and Ras/Raf/MEK/ERK pathways [2]. The 
p70S6K gene is amplified in approximately 9% of primary 
breast cancers and elevated levels of its mRNA transcripts 
are found in about 41% of the tumors [407,408]. It is 
known that some PTEN-deficient cells and tumors that 
are purported to grow in response to activated Akt are 
hypersensitive to mTOR inhibitors. p70S6K activity is 
reduced by mTOR inhibitors in PTEN-deficient cells and 
transgenic PTEN+/- mice [409,410].
CONCLUSIONS
In this review, we have discussed the various types 
of mutations which occur in the Ras/Raf/MEK/ERK and 
Ras/PI3K/Akt/mTOR pathways and how they can lead 
to cancer as well as other diseases. We discussed certain 
classes of genes important in cancer such as oncogenes, 
tumor suppressor, caretaker and gatekeeper genes. It 
is obvious that there are many genes which can fit into 
more than one category. We have introduced the concepts 
of driver, gatekeeper, passenger, lineage-specific and 
synthetic lethal mutations so that the reader will have 
a concept of how these different classes of mutations 
can contribute to cancer and have been used to identify 
key interacting genes. We have discussed the concepts 
of oncogene-addiction, oncogene-bypass and kinase-
switching and how they can be important in identifying the 
key components involved in the growth of the cancer cell 
and how they may change during treatment with targeted 
therapy. Mutations at many of the upstream receptor genes 
or RAS can result in abnormal Raf/MEK/ERK and PI3K/
PTEN/Akt/mTOR pathway activation. Hence targeting 
these cascade components with small-molecule inhibitors 
may inhibit cell growth. The usefulness of these inhibitors 
may depend on the mechanism of transformation of the 
particular cancer. If the tumor exhibits a dependency on 
the Ras/Raf/MEK/ERK pathway, then it may be sensitive 
to Raf and MEK inhibitors. In contrast, tumors that do 
not display enhanced expression of the Ras/Raf/MEK/
ERK pathway may not be sensitive to either Raf or MEK 
inhibitors but if the Ras/PI3K/Akt/mTOR pathway is 
activated, it may be sensitive to specific inhibitors that 
target this pathway. 
Some scientists and clinicians have considered that 
the simultaneous targeting of Raf and MEK by individual 
or dual inhibitors may be more effective in cancer 
therapy than just targeting Raf or MEK by themselves. 
This is based in part on the fact that there are intricate 
feed-back loops from ERK which can inhibit Raf and 
MEK. For example when MEK1 is targeted, ERK1,2 
is inhibited and the negative feed-back loop on MEK is 
broken and activated MEK accumulates. However, if Raf 
is also inhibited, it may be possible to completely shut 
down the pathway. This is a rationale for treatment with 
both MEK and Raf inhibitors or dual inhibitors. Likewise 
targeting both PI3K and mTOR may be more effective 
than targeting either PI3K or mTOR by themselves. If it 
is a single inhibitor which targets both molecules, such as 
the new PI3K and mTOR dual inhibitors this becomes a 
realistic therapeutic option. Finally, an emerging concept is 
the targeting of two different signal transduction pathways, 
Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR for example. 
This has been explored in some preclinical models as well 
as clinical trials. The rationale for the targeting of both 
pathways may be dependent on the presence of mutations 
in either/or both pathways or in upstream Ras in the 
particular cancer which can activate both pathways. The 
concepts of targeting these pathways is considered in more 
detail in an accompanying review [134].
ACKNOWLEDGMENTS
MC and GM were supported in 
part by grants from the Italian “Ministero 
dell’Istruzione, dell’Università e della Ricerca (Ministry 
for Education, Universities and Research) – MIUR” 
PRIN 2008 and FIRB-MERIT  n. RBNE08YYBM. 
MC was also supported in part by a grant to the CNR 
from the Italian Ministry of Economy and Finance for 
the Project FaReBio di Qualità. LC was supported in part 
by MIUR-PRIN 2009. ML was supported in part by a grant 
from the Italian Ministry of Health, Ricerca Finalizzata 
Stemness 2008 entitled “Molecular Determinants of 
Stemness and Mesenchymal Phenotype in Breast Cancer”. 
AMM was supported in part by grants from: MinSan 
2008 “Molecular therapy in pediatric sarcomas and 
leukemias against IGF-IR system: new drugs, best drug-
drug interactions, mechanisms of resistance and indicators 
of efficacy”, MIUR PRIN 2008 (2008THTNLC), 
and MIUR FIRB 2010 (RBAP10447J-003) and 2011 
(RBAP11ZJFA_001). MM was supported in part from 
the Italian Association for Cancer Research (AIRC), the 
Cariplo Foundation and the Italian Ministry of Health. AT 
was supported in part by grants from the Italian “Ministero 
dell’Istruzione, dell’Università e della Ricerca (Ministry 
Oncotarget 2012; 3: 954-987972www.impactjournals.com/oncotarget
for Education, University and Research) - MIUR - PRIN 
2008 and grant from “Sapienza”, University of Rome 
2009-11.
REFERENCE
1. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long 
J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, 
Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti 
F, Libra M, Milella M, et al. Roles of the Raf/MEK/ERK 
and PI3K/PTEN/Akt/mTOR pathways in controlling 
growth and sensitivity to therapy-implications for cancer 
and aging. Aging. 2011; 3: 192-222.  
2. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams 
SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone 
P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, 
Maksimovic-Ivanic D, Mijatovic S, et al. Ras/Raf/MEK/
ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and 
importance to inhibiting these pathways in human health. 
Oncotarget. 2011; 2: 135-164.
3. McCubrey JA, Steelman LS, Kempf CR, Chappell W, 
Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, 
Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, 
Cervello M, Cocco L, Martelli AM. Therapeutic resistance 
resulting from mutations in Raf/MEK/ERK and PI3K/
PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 2011; 
226: 2762-2781.
4. Little AS, Smith PD, Cook SJ. Mechanisms of acquired 
resistance to ERK1/2 pathway inhibitors. Oncogene. 2012 
May 7. doi: 10.1038/onc.2012.160.  
5. Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, 
Oroian D, Birtwistle MR, Buckhaults PJ. Novel somatic 
mutations to PI3K pathway genes in metastatic melanoma. 
PLoS One. 2012;7:e43369. 
6. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, 
Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, 
Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E et al. 
Passenger deletions generate therapeutic vulnerabilities in 
cancer. Nature. 2012;488:337-342.  
7. Blagosklonny MV. Increasing healthy lifespan by 
suppressing aging in our lifetime: preliminary proposal. 
Cell Cycle. 2010; 9: 4788-4794. 
8. Blagosklonny MV. Progeria, rapamycin and normal aging: 
recent breakthrough. Aging. 2011; 3: 685-691. 
9. Blagosklonny MV. The power of chemotherapeutic 
engineering: arresting cell cycle and suppressing senescence 
to protect from mitotic inhibitors. Cell Cycle. 2011; 10: 
2295-2298.
10. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic 
instability--an evolving hallmark of cancer. Nat Rev Mol 
Cell Biol. 2010; 11: 220-228.
11. Caponigro G, Sellers WR. Advances in the preclinical 
testing of cancer therapeutic hypotheses. Nat Rev Drug 
Discov. 2011; 10: 179-187.
12. Torkamani A, Schork NJ. Identification of rare cancer 
driver mutations by network reconstruction Genome Res. 
2009; 19: 1570–1578.
13. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, 
Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz 
D, Springer C, Marais R. Gatekeeper mutations mediate 
resistance to BRAF-targeted therapies. Sci Transl Med. 
2010; 2: 35ra41.
14. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, 
Soua Z, McCubrey JA, Travali S, Libra M. Gene alterations 
in the PI3K/PTEN/AKT pathway as a mechanism of drug-
resistance. Int J Oncol. 2012, 40: 639-644.
15. Chan DA, Giaccia AJ. Harnessing synthetic lethal 
interactions in anticancer drug discovery.  Nat Rev Drug 
Discov. 2011; 10: 351-364.
16. Weidle UH, Maisel D, Eick D. Synthetic lethality-based 
targets for discovery of new cancer therapeutics. Cancer 
Genomics Proteomics. 2011; 8: 159-171.
17. Janes KA. RUNX1 and its understudied role in breast 
cancer.  Cell Cycle. 2011; 10: 3461-3465. 
18. Bauzon F, Zhu L. Racing to block tumorigenesis after 
pRb loss: an innocuous point mutation wins with synthetic 
lethality.  Cell Cycle. 2010; 9: 2118-2123. 
19. Taricani L. Shanahan F, Pierce RH, Guzi TJ, Parry D. 
Phenotypic enhancement of thymidylate synthetase pathway 
inhibitors following ablation of Neil1 DNA glycosylase/
lyase. Cell Cycle. 2010; 9: 4876-4883.
20. Wellbrock C, Rana S, Paterson H, Pickersgill H, 
Brummelkamp T, Marais R. Oncogenic BRAF regulates 
melanoma proliferation through the lineage specific factor 
MITF. PLoS One. 2008; 3: e2734.
21. Weinstein IB, Joe A. Oncogene Addiction. Cancer Res. 
2008; 68: 3077-3080.
22. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland 
C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, 
Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, 
Lee C et al. MET amplification leads to gefitinib resistance 
in lung cancer by activating ERBB3 signaling. Science. 
2007;316:1039-1043 . 
23. Faber AC, Wong KK. Engelman JA. Differences underlying 
EGFR and HER2 oncogene addiction. Cell Cycle. 2010; 9: 
851-852.
24. Lee JT, Shan J, Gu W. Targeting the degradation of cyclin 
D1 will help to eliminate oncogene addiction. Cell Cycle. 
2010; 9: 857-858.
25. Sharma SV, Settleman J. Exploiting the balance between 
life and death: targeted cancer therapy and “oncogenic 
shock”. Biochem Pharmacol. 2010; 80: 666-673.
26. Luo J, Solimini NL, Elledge SJ. Principles of cancer 
therapy: oncogene and non-oncogene addiction. Cell. 2009; 
136: 823-837.  
27. Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR 
inhibitor resistance in cancer therapy. Target Oncol. 2011; 
6: 17-270.
Oncotarget 2012; 3: 954-987973www.impactjournals.com/oncotarget
28. Villanueva J, Vultur A, Lee JT, Somasundaram R, 
Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu 
X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, 
D’Andrea K, Pushparajan A, Hayden JE, Brown KD et al. 
Acquired resistance to BRAF inhibitors mediated by a RAF 
kinase switch in melanoma can be overcome by cotargeting 
MEK and IGF-1R/PI3K.  Cancer Cell.2010;18:683-695 .
29. Simmons GW, Pong WW, Emnett RJ, White CR, Gianino 
SM, Rodriguez FJ, Gutmann DH. Neurofibromatosis-1 
heterozygosity increases microglia in a spatially and 
temporally restricted pattern relevant to mouse optic glioma 
formation and growth. J Neuropathol Exp Neurol. 2011; 70: 
51-62. 
30. Dbouk HA, Backer JM. A beta version of life: p110beta 
takes center stage. Oncotarget. 2010; 1: 729-733. 
31. Fidalgo da Silva E, Ansari SB, Maimaiti J, Barnes EA, 
Kong-Beltran M, Donoghue DJ, Porter LA. The tumor 
suppressor tuberin regulates mitotic onset through the 
cellular localization of cyclin B1. Cell Cycle. 2011; 10: 
3129-3139. 
32. Searle JS, Li B, Du W. Targeting Rb mutant cancers by 
inactivating TSC2. Oncotarget. 2010; 1: 228-232.   
33. Mavrakis KJ, Leslie CS, Wendel HG.  Cooperative control 
of tumor suppressor genes by a network of oncogenic 
microRNAs. Cell Cycle. 2011; 10: 2845-2849.
34. Hayashi K, Shibata K, Morita T, Iwasaki K, Watanabe M, 
Sobue K. Insulin receptor substrate-1/SHP-2 interaction, a 
phenotype-dependent switching machinery of insulin-like 
growth factor-I signaling in vascular smooth muscle cells. J 
Biol Chem. 2004; 279: 40807-40818. 
35. Duncan CG, Killela PJ, Payne CA, Lampson B, Chen 
WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory 
SG, McDonald KL, McLendon RE, Bigner DD, Yan H. 
Integrated genomic analyses identify ERRFI1 and TACC3 
as glioblastoma-targeted genes. Oncotarget. 2010; 1: 265-
277. 
36. Dienstmann R, Martinez P, Felip E. Personalizing therapy 
with targeted agents in non-small cell lung cancer. 
Oncotarget. 2011; 2: 165-177. 
37. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen 
JG, Grimberg A, El-Deiry WS. Human colon cancer stem 
cells are enriched by insulin-like growth factor-1 and are 
sensitive to figitumumab. Cell Cycle. 2011; 10: 2331-2338. 
38. Novosyadlyy R, LeRoith D.  Hyperinsulinemia and type 2 
diabetes: impact on cancer. Cell Cycle. 2010; 9: 1449-1450.
39. Salzano M, Rusciano MR, Russo E, Bifulco M, Postiglione 
L, Vitale M. Calcium/calmodulin-dependent protein kinase 
II (CaMKII) phosphorylates Raf-1 at serine 338 and 
mediates Ras-stimulated Raf-1 activation. Cell Cycle. 2012; 
11: 2100-2106.
40. Nucera C, Lawler J, Hodin R, Parangi S. The BRAFV600E 
mutation: what is it really orchestrating in thyroid cancer?.
Oncotarget. 2010; 1: 751-756.
41. Abraham D, Podar K, Pacher M, Kubicek M, Welzel N, 
Hemmings BA, Dilworth SM, Mischak H, Kolch W, 
Baccarini M.  Raf-1-associated protein phosphatase 2A as a 
positive regulator of kinase activation. J Biol Chem. 2000; 
275: 22300-22304. 
42. Mischak H, Seitz T, Janosch P, Eulitz M, Steen H, 
Schellerer M, Philipp A, Kolch W. Negative regulation 
of Raf-1 by phosphorylation of serine 621. Mol Cell Biol. 
1996; 10: 5409-5418.
43. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a 
drugable tumor suppressor in Ph1(+) leukemias. Cancer 
Metastasis Rev. 2008; 27: 159-168.
44. Brennan DF, Dar AC, Hertz NT, Chao WC, Burlingame 
AL, Shokat KM, Barford D. A Raf-induced allosteric 
transition of KSR stimulates phosphorylation of MEK. 
Nature. 2011; 472: 366-369.
45. Ritt DA, Daar IO, Morrison DK. KSR regulation of the 
Raf-MEK-ERK cascade. Methods Enzymol.2006; 407: 
224-237.
46. McKay MM, Ritt DA, Morrison DK. RAF inhibitor-
induced KSR1/B-RAF binding and its effects on ERK 
cascade signaling.  Curr Biol. 2011; 21: 563-568. 
47. Melissa M McKay, Alyson K Freeman, and Deborah K 
Morrison Complexity in KSR function revealed by Raf 
inhibitor and KSR structure studies Small Gtpases. 2011; 
2: 276–281.
48. Smith FD, Langeberg LK, Scott JD. 
Plugging PKA into ERK scaffolds. 
Cell Cycle. 2011; 10: 731-732. 
49. Pao W, Girard N. New driver mutations in non-small-cell 
lung cancer. Lancet Oncol. 2011; 12: 175-180.
50. Eblen ST, Slack JK, Weber MJ, Catling AD. Rac-PAK 
signaling stimulates extracellular signal-regulated kinase 
(ERK) activation by regulating formation of MEK1-ERK 
complexes.  Mol Cell Biol 2002; 22: 6023-6033.
51, Mack NA. Whalley HJ. Castillo-Lluva S. Malliri A. The 
diverse roles of Rac signaling in tumorigenesis. Cell Cycle. 
2011; 10: 1571-181.
52. Xing J, Ginty DD, Greenberg ME.  Coupling of the Ras-
MAPK pathway to gene activation by Rsk2, a growth factor 
regulated CREB kinase. Science. 1996; 273: 959-963. 
53. Balan V, Leicht DT, Zhu J, Balan K, Kaplun A, 
Singh-Gupta V, Qin J, Ruan H, Comb MJ, Tzivion G. 
Identification of novel in vivo Raf-1 phosphorylation 
sites mediating positive feedback Raf-1 regulation by 
extracellular signal-regulated kinase. Mol Biol Cell. 2006; 
17: 1141-1153. 
54. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou 
XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, 
Morrison DK. Regulation of Raf-1 by direct feedback 
phosphorylation. Mol Cell. 2005; 17: 215-224.  
55. Catalanotti, F, Reyes G, Jesenberger V Galabova-Kovacs G, 
de Matos Simoes R, Carugo O, Baccarini M. A Mek1-Mek2 
heterodimer determines the strength and duration of the Erk 
signal. Nat Struct Mol Biol. 2009; 16: 294-303. 
Oncotarget 2012; 3: 954-987974www.impactjournals.com/oncotarget
56. Sturm OE, Orton R, Grindlay J, Birtwistle M, Vyshemirsky 
V, Gilbert D, Calder M, Pitt A, Kholodenko B, Kolch W. 
The mammalian MAPK/ERK pathway exhibits properties 
of a negative feedback amplifier.  Sci Signal. 2010; 3: ra90.
57. Buday L, Warne PH, Downward J. Downregulation of the 
Ras activation pathway by MAP kinase phosphorylation of 
Sos. Oncogene. 1995;11:1327-1331.
58. Li X, Huang Y, Jiang J, Frank SJ. ERK-dependent threonine 
phosphorylation of EGF receptor modulates receptor 
downregulation and signaling. Cell Signal. 2008;20:2145-
2155.
59. Ekerot M, Stavridis MP, Delavaine L, Mitchell MP, Staples 
C, Owens DM, Keenan ID, Dickinson RJ, Storey KG, 
Keyse SM. Negative-feedback regulation of FGF signalling 
by DUSP6/MKP-3 is driven by ERK1/2 and mediated by 
Ets factor binding to a conserved site within the DUSP6/
MKP-3 gene promoter. Biochem J. 2008;412:287-298. 
60. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. 
Potential tumor suppressive pathway involving DUSP6/
MKP-3 in pancreatic cancer. Am J Pathol. 2003;162:1807-
1815.
61. Fischer A, Baljuls A, Reinders J, Nekhoroshkova E, 
Sibilski C, Metz R, Albert S, Rajalingam K, Hekman M, 
Rapp UR. Regulation of RAF activity by 14-3-3 proteins: 
RAF kinases associate functionally with both homo- and 
heterodimeric forms of 14-3-3 proteins. J Biol Chem. 2009; 
284: 3183-3194.
62. Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss 
A, Weber MJ. MP1: a MEK binding partner that enhances 
enzymatic activation of the MAP kinase cascade. Science. 
1998; 281: 1668-1671.  
63. Grammatikakis N, Lin JH, Grammatikakis A, Tsichlis PN, 
Cochran BH. p50(cdc37) acting in concert with Hsp90 is 
required for Raf-1 function. Mol Cell Biol. 1999; 19: 1661-
1672. 
64. Goettel JA, Liang D, Hilliard VC, Edelblum KL, Broadus 
MR, Gould KL, Hanks SK, Polk DB. KSR1 is a functional 
protein kinase capable of serine autophosphorylation and 
direct phosphorylation of MEK1 find rest of reference Exp 
Cell Res. 2011; 317: 452-463.
65. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, 
Sedivy JM, Kolch W.  Mechanism of suppression of the 
Raf/MEK/extracellular signal-regulated kinase pathway by 
the raf kinase inhibitor protein.  Mol Cell Biol. 2000; 20: 
3079-3085. 
66. Mollapour M, Tsutsumi S, Neckers L. Hsp90 
phosphorylation, Wee1 and the cell cycle. Cell Cycle. 2010; 
9: 2310-2316.   
67. Tao YJ. Zheng W. Chaperones and the maturation of steroid 
hormone receptor complexes. Oncotarget. 2011; 2: 104-
106.
68. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer 
M, Li D, Ullrich R, Koker M, Fischer F, Shimamura T, 
Rauh D, Mermel C, Fischer S, Stückrath I, Heynck S, et al. 
Predicting drug susceptibility of non-small cell lung cancers 
based on genetic lesions. J Clin Invest. 2009; 119: 1727-
1740.
69. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting 
the dynamic HSP90 complex in cancer. Nature Reviews 
Cancer. 2010; 10: 537-549.
70. Rajalingam K, Wunder C, Brinkmann V, Churin Y, 
Hekman M, Sievers C, Rapp UR, Rudel T. Prohibitin is 
required for Ras-induced Raf-MEK-ERK activation and 
epithelial cell migration. Nat Cell Biol. 2005; 7: 837-843. 
71. Sanz-Moreno V, Casar B, Crespo P. p38alpha isoform 
Mxi2 binds to extracellular signal-regulated kinase 1 and 
2 mitogen-activated protein kinase and regulates its nuclear 
activity by sustaining its phosphorylation levels.  Mol Cell 
Biol. 2003; 23: 3079-3090.
72. Casar B, Sanz-Moreno V, Yazicioglu MN, Rodríguez 
J, Berciano MT, Lafarga M, Cobb MH, Crespo P. Mxi2 
promotes stimulus-independent ERK nuclear translocation. 
EMBO J. 2007; 26: 635-646.
73. Casar B, Rodríguez J, Gibor G, Seger R, Crespo P. Mxi2 
sustains ERK1/2 phosphorylation in the nucleus by 
preventing ERK1/2 binding to phosphatases.  Biochem J. 
2012; 441: 571-578.
74. Cheng J, Zhang C, Shapiro DJ. A functional serine 118 
phosphorylation site in estrogen receptor-alpha is required 
for down-regulation of gene expression by 17beta-estradiol 
and 4-hydroxytamoxifen. Endocrinology. 2007; 148: 4634-
4641.
75. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic 
PM, Blalock WL, Franklin RA, McCubrey JA. Signal 
transduction mediated by the Ras/Raf/MEK/ERK pathway 
from cytokine receptors to transcription factors: potential 
targeting for therapeutic intervention. Leukemia. 2003; 17: 
1263-1293.
76. Wang Z, Ge L, Wang M, Carr BI. Phosphorylation regulates 
Myc expression via prolonged activation of the mitogen-
activated protein kinase pathway. J Cell Physiol. 2006; 208: 
133-140.
77. Hong J, Zhou J, Fu J, He T, Qin J, Wang L, Liao L, Xu 
J. Phosphorylation of serine 68 of Twist1 by MAPKs 
stabilizes Twist1 protein and promotes breast cancer cell 
invasiveness. Cancer Res. 2011; 71: 3980-3990.
78. Turner FE, Broad S, Khanim FL, Jeanes A, Talma S, 
Hughes S, Tselepis C, Hotchin NA. Slug regulates integrin 
expression and cell proliferation in human epidermal 
keratinocytes. J Biol Chem. 2006; 281: 21321-21331.
79. Chen H, Zhu G, Li Y, Padia RN, Dong Z, Pan ZK, 
Liu K, Huang S. Extracellular signal-regulated kinase 
signaling pathway regulates breast cancer cell migration by 
maintaining slug expression. Cancer Res. 2009; 69: 9228-
9235.
80. Nagarajan D, Melo T, Deng Z, Almeida C, Zhao W. ERK/
GSK3-beta/Snail signaling mediates radiation-induced 
alveolar epithelial-to-mesenchymal transition. Free Radic 
Oncotarget 2012; 3: 954-987975www.impactjournals.com/oncotarget
Biol Med. 2012; 52: 983-992.
81. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, 
Kimbro KS, Tighiouart M, Liu T, Simons JW, O’Regan 
RM. Insulin-like growth factor-I-dependent up-regulation 
of ZEB1 drives epithelial-to-mesenchymal transition in 
human prostate cancer cells.  Cancer Res. 2008; 68: 2479-
2488.
82. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. 
ERK2 but not ERK1 induces epithelial-to-mesenchymal 
transformation via DEF motif-dependent signaling events. 
Mol Cell. 2010; 38: 114-1127.
83. Shin S, Blenis J. ERK2/Fra1/ZEB pathway induces 
epithelial-to-mesenchymal transition. Cell Cycle. 2010; 9: 
2483-2484.  
84. Smit MA, Peeper DS. Epithelial-mesenchymal transition 
and senescence: two cancer-related processes are crossing 
paths. Aging. 2010; 2: 735-741.  
85. Browne G, Sayan AE, Tulchinsky E. ZEB proteins link cell 
motility with cell cycle control and cell survival in cancer. 
Cell Cycle. 2010; 9: 886-891. 
86. Yang DJ, Chung JY, Lee SJ, Park SY, Pyo JH, Ha NC, 
Yoo MA, Park BJ. Slug, mammalian homologue gene of 
Drosophila escargot, promotes neuronal-differentiation 
through suppression of HEB/daughterless. Cell Cycle. 
2010; 9: 2789-2802. 
87. Jordan NV, Johnson GL, Abell AN. Tracking the 
intermediate stages of epithelial-mesenchymal transition 
in epithelial stem cells and cancer.  Cell Cycle. 2011; 10: 
2865-2873. 
88. Baritaki S, Huerta-Yepez S, Sahakyan A, Karagiannides I, 
Bakirtzi K, Jazirehi A, Bonavida B. Mechanisms of nitric 
oxide-mediated inhibition of EMT in cancer: inhibition of 
the metastasis-inducer Snail and induction of the metastasis-
suppressor RKIP. Cell Cycle. 2010; 9: 4931-4940.
89. Perez-Losada J, Sanchez-Garcia I. New functions for the 
Snail family of transcription factors: Two-faced proteins. 
Cell Cycle. 2010; 9: 2706-2708. 
90. Velpula KK, Dasari VR, Tsung AJ, Dinh DH, Rao JS. Cord 
blood stem cells revert glioma stem cell EMT by down 
regulating transcriptional activation of Sox2 and Twist1. 
Oncotarget. 2011; 2: 1028-1042.
91. Gasparotto D, Polesel J, Marzotto A, Colladel R, Piccinin 
S, Modena P, Grizzo A, Sulfaro S, Serraino D, Barzan 
L, Doglioni C, Maestro R. Overexpression of TWIST2 
correlates with poor prognosis in head and neck squamous 
cell carcinomas. Oncotarget. 2011; 2: 1165-1175. 92. Eckert 
MA, Yang J. Targeting invadopodia to block breast cancer 
metastasis. Oncotarget. 2011; 2: 562-568. 
93. Kyriakis JM, Avruch J. Mammalian mitogen-activated 
protein kinase signal transduction pathways activated by 
stress and inflammation. Physiol Rev. 2001; 81: 807-869.
94. Roux PP, Blenis J. ERK and p38 MAPK-activated protein 
kinases: a family of protein kinases with diverse biological 
functions. Microbiol Mol Biol Rev. 2004; 68: 320-344.
95. Gupta P, Prywes R. ATF1 phosphorylation by the ERK 
MAPK pathway is required for epidermal growth factor-
induced c-jun expression. J Biol Chem. 2002; 277: 50550-
50556.
96. Costello PS, Nicolas RH, Watanabe Y, Rosewell I, 
Treisman R.  Ternary complex factor SAP-1 is required for 
Erk-mediated thymocyte positive selection. Nat Immunol. 
2004; 5: 289-298.
97. Costello P, Nicolas R, Willoughby J, Wasylyk B, Nordheim 
A, Treisman R. Ternary complex factors SAP-1 and Elk-
1, but not net, are functionally equivalent in thymocyte 
development. J Immunol. 2010; 185: 1082-1092.
98. Mylona A, Nicolas R, Maurice D, Sargent M, Tuil D, 
Daegelen D, Treisman R, Costello P.The essential function 
for SRF in T cell development reflects its specific coupling 
to ERK signalling. Mol and Cell Biol. 2010; 31: 267-276.
99. Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional 
crosstalk between TGF-beta and stem cell pathways 
in tumor cell invasion: role of EMT promoting Smad 
complexes. Cell Cycle. 2010; 9: 2363-2374. 
100. Arthur JS.  MSK activation and physiological roles. Front 
Biosci. 2008; 13: 5866-5879.
101. Cuevas BD, Abell AN, Witowsky JA, Yujiri T, Johnson 
NL, Kesavan K, Ware M, Jones PL, Weed SA, DeBiasi RL, 
Oka Y, Tyler KL, Johnson GL. MEKK1 regulates calpain-
dependent proteolysis of focal adhesion proteins for rear-
end detachment of migrating fibroblasts. EMBO J. 2003; 
22: 3346-3355.
102. Zheng Y, Xia Y, Hawke D, Halle M, Tremblay ML, Gao 
X, Zhou XZ, Aldape K, Cobb MH, Xie K, He J, Lu Z. FAK 
Phosphorylation by ERK primes Ras-induced tyrosine 
dephosphorylation of FAK mediated by PIN1 and PTP-
PEST. Mol Cell. 2009; 35: 11-25.
103. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner 
CE, Parsons JT, Horwitz AF. FAK-Src signalling through 
paxillin, ERK and MLCK regulates adhesion disassembly. 
Nat Cell Biol. 2004; 6: 154-1561.
104. Zheng Y, Yang W, Xia Y, Hawke D, Liu DX, Lu Z. Ras-
induced and extracellular signal-regulated kinase 1 and 
2 phosphorylation-dependent isomerization of protein 
tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK 
dephosphorylation by PTP-PEST. Mol Cell Biol. 2011; 31: 
4258-4269.
105. Abrams SL, Steelman LS, Shelton JG, Wong ET, Chappell 
WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, 
Martelli AM, McCubrey JA. The Raf/MEK/ERK pathway 
can govern drug resistance, apoptosis and sensitivity to 
targeted therapy. Cell Cycle. 2010; 9: 1781-1791. 
106. Steelman LS, Abrams SL, Shelton JG, Chappell WH, 
Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, 
Martelli AM, McCubrey JA. Dominant roles of the Raf/
MEK/ERK pathway in cell cycle progression, prevention 
of apoptosis and sensitivity to chemotherapeutic drugs. Cell 
Cycle. 2010; 9: 1629-1638. 
Oncotarget 2012; 3: 954-987976www.impactjournals.com/oncotarget
107. Abrams SL, Steelman LS, Shelton JG, Chappell WH, 
Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, 
Martelli AM, McCubrey JA. Enhancing therapeutic efficacy 
by targeting non-oncogene addicted cells with combinations 
of signal transduction inhibitors and chemotherapy. Cell 
Cycle. 2010; 9: 1839-46.  
108. Kolesnichenko M, Vogt PK. Understanding PLZF: two 
transcriptional targets, REDD1 and smooth muscle alpha-
actin, define new questions in growth control, senescence, 
self-renewal and tumor suppression. Cell Cycle. 10(5):771-
5, 
109. Campaner S. Doni M. Verrecchia A. Faga G. Bianchi L. 
Amati B. Myc, Cdk2 and cellular senescence: Old players, 
new game. Cell Cycle. 2011; 9: 3655-3661.  
110. Bansal R, Nikiforov MA. Pathways of oncogene-induced 
senescence in human melanocytic cells.  Cell Cycle. 2010; 
9: 2782-2788. 
111. Miller KR, Kelley K, Tuttle R, Berberich SJ. HdmX 
overexpression inhibits oncogene induced cellular 
senescence. Cell Cycle. 2010; 9: 3376-3382. 
112. Kosar M, Bartkova J, Hubackova S, Hodny Z, Lukas J, 
Bartek J. Senescence-associated heterochromatin foci are 
dispensable for cellular senescence, occur in a cell type- 
and insult-dependent manner and follow expression of 
p16(ink4a). Cell Cycle. 2011; 10: 457-468. 
113. Taylor JR, Lehmann BD, Chappell WH, Abrams SL, 
Steelman LS, McCubrey JA. Cooperative effects of Akt-
1 and Raf-1 on the induction of cellular senescence in 
doxorubicin or tamoxifen treated breast cancer cells. 
Oncotarget. 2011; 2: 610-626. 
114. Borras C, Monleon D, Lopez-Grueso R, Gambini J, Orlando 
L, Pallardo FV, Santos E, Vina J, Font de Mora J. RasGrf1 
deficiency delays aging in mice. Aging. 2011; 3: 262-276. 
115. de Magalhaes JP. A role for Ras signaling in modulating 
mammalian aging by the GH/IGF1 axis. Aging. 2011; 3: 
336-337. 
116. Mirisola MG, Longo VD. Conserved role of Ras-GEFs in 
promoting aging: from yeast to mice. Aging. 2011; 3: 340-
343. 
117. Ratajczak MZ, Kucia M, Liu R, Shin DM, Bryndza E, 
Masternak MM, Tarnowski M, Ratajczak J, Bartke A. 
RasGrf1: genomic imprinting, VSELs, and aging. Aging. 
2011; 3: 692-697.
118. Rongo C. Epidermal growth factor and aging: a signaling 
molecule reveals a new eye opening function. Aging. 2011; 
3: 896-905. 
119. Qiu W, Sahin F, Iacobuzio-Donahue CA, Garcia-
Carracedo D, Wang WM, Kuo CY, Chen D, Arking DE, 
Lowy AM, Hruban RH, Remotti HE, Su GH. Disruption 
of p16 and activation of Kras in pancreas increase ductal 
adenocarcinoma formation and metastasis in vivo. 
Oncotarget. 2011; 2: 862-873. 
120. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg 
S, Teague J, Woffendin H, Garnett MJ, Bottomley W, 
Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et 
al. Mutations of the BRAF gene in human cancer. Nature. 
2002; 417: 949-954.
121. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, 
Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, 
Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini 
F, Pinchera A, et al. BRAF(V599E) mutation is the leading 
genetic event in adult sporadic papillary thyroid carcinomas. 
J Clin Endocrinol Metab. 2004; 89: 2414-2420.
122. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, 
Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson 
KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, 
Fleming MD, Rollins BJ. Recurrent BRAF mutations in 
Langerhans cell histiocytosis. Blood. 2010; 116: 1919-
1923.
123. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero 
R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, 
Albelda SM, Davies H, Cox C, Brignell G, Stephens P, et 
al. BRAF and RAS mutations in human lung cancer and 
melanoma. Cancer Res. 2002; 62: 6997-7000.
124. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic 
colorectal cancer. N Engl J Med. 2009; 361: 98-99.
125. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, 
Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells 
VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, 
Liso A, Ambrosetti A, et al. BRAF mutations in hairy-cell 
leukemia. N Engl J Med. 2011; 364: 2305–2315.
126. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, 
Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann 
GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker 
A, Bergsagel PL, Bernstein BE, et al. Initial genome 
sequencing and analysis of multiple myeloma. Nature. 
2011; 471: 467-472.
127. Case M, Matheson E, Minto L, Hassan R, Harrison CJ, 
Bown N, Bailey S, Vormoor J, Hall AG, Irving JA. 
Mutation of genes affecting the RAS pathway is common in 
childhood acute lymphoblastic leukemia. Cancer Res. 2008; 
68: 6803-6809.
128. Gustafsson B, Angelini S, Sander B, Christensson B, 
Hemminki K , Kumar R. Mutations in the BRAF and 
N-ras genes in childhood acute lymphoblastic leukaemia. 
Leukemia. 2005; 19: 310-312. 
129. Davidsson J, Lilljebjorn H, Panagopoulos I, Fioretos T, 
Johansson B. BRAF mutations are very rare in B- and 
T-cell pediatric acute lymphoblastic leukemias. Leukemia. 
2008; 22: 1619-1621. 
130. Lee JW, Yoo NJ, Soung YH, Kim HS, Park WS, Kim SY, 
Lee JH, Park JY, Cho YG, Kim CJ, Ko YH, Kim SH, Nam 
SW, Lee JY, Lee SH. BRAF mutations in non-Hodgkin’s 
lymphoma. Br J Cancer. 2003; 89: 1958-1960.
131. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, 
Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, 
Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou 
L, Gould J, et al. Discovery and prioritization of somatic 
Oncotarget 2012; 3: 954-987977www.impactjournals.com/oncotarget
mutations in diffuse large B-cell lymphoma (DLBCL) by 
whole-exome sequencing. Proc Natl Acad Sci U S A. 2012; 
109: 3879-3884.
132. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh 
J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, 
Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi 
M, Gazdar A, Rosen N, et al. Genetic predictors of MEK 
dependence in non-small cell lung cancer. Cancer Res. 
2008; 68: 9375-9383.
133. Estep AL, Palmer C, McCormick F, Rauen KA.  Mutation 
Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer 
Cell Lines: Implications for Therapy. PLoS ONE. 2007; 2: 
e1279. doi:10.1371/journal.pone.0001279 
134. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, 
Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte 
G, Mazzarino MC, Candido S, Libra M, Bäsecke J, 
Mijatovic S, Maksimovic-Ivanic D,  Cocco L, et al. Ras/
Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade 
Inhibitors: Targeting these pathways for cancer treatment 
and overcoming therapy resistance. Oncotarget 2012; In 
Press.
135. Martelli AM, Evangelisti C, Chappell W, Abrams SL, 
Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, 
Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, 
McCubrey JA. Targeting the translational apparatus to 
improve leukemia therapy: roles of the PI3K/PTEN/Akt/
mTOR pathway. Leukemia. 2011; 25: 1064-1079.
136. Martelli AM, Chiarini F, Evangelisti C, Cappellini A, 
Buontempo F, Bressanin D, Fini M,   McCubrey JA. Dual 
Inhibitors of phosphatidylinositol 3-kinase and mammalian 
target of rapamycin: a novel therapeutic strategy for acute 
leukemia treatment? Oncotarget. 2012; 3: 371-394.
137. Cervello M, McCubrey JA, Cusimano A, Lampiasi 
N, Azzolina A, Montalto G. Targeted therapy for 
hepatocellular carcinoma: novel agents on the horizon. 
Oncotarget. 2012; 3: 236-260.
138. Martelli AM, Chiarini F, Evangelisti C, Ognibene 
A, Bressanin D, Billi AM, Manzoli L,  Cappellini A, 
McCubrey JA. Targeting the Liver Kinase B1/AMP-
Dependent Kinase pathway as a Therapeutic Strategy for 
Hematological Malignancies. Expert Opinion Therapeutic 
Targets. 2012; 16: 729-742.
139. Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan 
SE. Elevated PI3K signaling drives multiple breast cancer 
subtypes. Oncotarget. 2011; 2: 435-447.
140. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, 
Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans 
WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, 
Mills GB, Phillips WA, et al. PIK3CA mutations associated 
with gene signature of low mTORC1 signaling and better 
outcomes in estrogen receptor-positive breast cancer. Proc 
Natl Acad Sci U S A. 2010; 107: 10208-10213.
141. Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza 
MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris 
MG. Coexistence of PIK3CA and other oncogene mutations 
in lung adenocarcinoma-rationale for comprehensive 
mutation profiling. Mol Cancer Ther. 2012; 11: 485-491.
142. Alessi DR, James SR, Downes CP, Holmes AB, 
Gaffney PR, Reese CB, Cohen P. Characterization of 
a 3-phosphoinositide-dependent protein kinase which 
phosphorylates and activates protein kinase Balpha. Curr 
Biol. 1997; 7: 261-269. 
143. Anderson DH. p85 plays a critical role in controlling 
flux through the PI3K/PTEN signaling axis through dual 
regulation of both p110 (PI3K) and PTEN. Cell Cycle. 
2010; 9: 2055-2056.
144. Coffer PJ, Woodgett JR. Molecular cloning and 
characterisation of a novel putative protein-serine kinase 
related to the cAMP-dependent and protein kinase C 
families. Eur J Biochem. 1991; 201: 475-481.
145. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein 
kinase B signalling: AKTion on multiple fronts. Trends 
Biochem Sci. 2004; 29: 233-242.
146. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role 
of PI3K and AKT specific isoforms in ovarian cancer cell 
migration, invasion and proliferation through the p70S6K1 
pathway. Cell Signal. 2006; 18: 2262-2271.
147. Gonzalez E, McGraw TE. The Akt kinases: isoform 
specificity in metabolism and cancer. Cell Cycle. 2009; 8: 
2502-2508.
148. Yang WL, Wu CY, Wu J, Lin HK. Regulation of Akt 
signaling activation by ubiquitination. Cell Cycle. 2010; 9: 
487-497.
149. Du K, Montminy M. CREB is a regulatory target for the 
protein kinase Akt/PKB. J Biol Chem. 1998; 273: 32377-
32379. 
150. Brennan P, Babbage JW, Burgering BM, Groner B, Reif 
K, Cantrell DA. Phosphatidylinositol 3-kinase couples 
the interleukin-2 receptor to the cell cycle regulator E2F. 
Immunity. 1997; 7: 679-689. 
151. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-
kappaB by the Akt/PKB kinase. Curr Biol. 1999; 9: 601-
604. 
152. Buitenhuis M, Coffer PJ. The role of the PI3K-PKB 
signaling module in regulation of hematopoiesis. Cell 
Cycle. 2009; 8: 560-566. 
153. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nuñez 
G. Interleukin-3-induced phosphorylation of BAD through 
the protein kinase Akt. Science. 1997;278: 687-689. 
154. Cross DA, Alessi DR, Cohen P, Andjelkovich M, 
Hemmings BA. Inhibition of glycogen synthase kinase-3 
by insulin mediated by protein kinase B. Nature. 1995; 378: 
785-789. 
155. Steelman LS, Navolanic P, Chappell WH, Abrams SL, 
Wong EWT, Martelli AM, Cocco L, Stivala F, Libra M, 
Nicoletti F, Drobot LB,  Franklin RA, McCubrey JA. 
Involvement of Akt and mTOR in chemotherapeutic- and 
hormonal-based drug resistance and response to radiation 
in breast cancer cells. Cell Cycle. 2011; 10; 3003-3015. 
Oncotarget 2012; 3: 954-987978www.impactjournals.com/oncotarget
156. Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, 
Martelli AM, Stivala F, Libra M,  Nicoletti F,  Drobot LB, 
Franklin RA, Steelman LS, McCubrey JA. Involvement 
of Akt-1 and mTOR in Sensitivity of Breast Cancer to 
Targeted Therapy. Oncotarget. 2011; 2: 538-550. 
157. Ambs S, Glynn SA. Candidate pathways linking inducible 
nitric oxide synthase to a basal-like transcription pattern 
and tumor progression in human breast cancer. Cell Cycle. 
2011; 10: 619-624. 
158. Nowicki TS, Zhao H, Darzynkiewicz Z, Moscatello A, 
Shin E, Schantz S, Tiwari RK, Geliebter J. Downregulation 
of uPAR inhibits migration, invasion, proliferation, FAK/
PI3K/Akt signaling and induces senescence in papillary 
thyroid carcinoma cells. Cell Cycle. 2011; 10: 100-107. 
159. Hayashi M. Yoo YY. Christensen J. Huang LE. 
Requirement of evading apoptosis for HIF-1alpha-induced 
malignant progression in mouse cells. Cell Cycle. 2011; 10: 
2364-2372. 
160. Erol A. Genotoxic stress-mediated cell cycle activities for 
the decision of cellular fate. Cell Cycle. 2011; 10: 3239-
3248. 
161. Khalil A, Morgan RN, Adams BR, Golding SE, Dever 
SM, Rosenberg E, Povirk LF, Valerie K. ATM-dependent 
ERK signaling via AKT in response to DNA double-strand 
breaks. Cell Cycle. 2011; 10: 481-491. 
162. Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, 
Bristow RG. MRE11 promotes AKT phosphorylation in 
direct response to DNA double-strand breaks. Cell Cycle. 
2011; 10: 2218-2232. 
163. Wani R, Bharathi NS, Field J, Tsang AW, Furdui CM. 
Oxidation of Akt2 kinase promotes cell migration and 
regulates G1-S transition in the cell cycle. Cell Cycle. 2011; 
10: 3263-3268. 
164. Kandouz M, Haidara K, Zhao J, Brisson ML, Batist G. The 
EphB2 tumor suppressor induces autophagic cell death via 
concomitant activation of the ERK1/2 and PI3K pathways 
Cell Cycle. 2010; 9: 398-407. 
165. Sayed D, Abdellatif M. AKT-ing via microRNA. Cell 
Cycle. 2010; 9: 3213-3217. 
166. Xiang L, Nakamura Y, Lim YM, Yamasaki Y, Kurokawa-
Nose Y, Maruyama W, Osawa T, Matsuura A, Motoyama 
N, Tsuda L. Tetrahydrocurcumin extends life span and 
inhibits the oxidative stress response by regulating the 
FOXO forkhead transcription factor. Aging. 2011; 3: 1098-
1109. 
167. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway 
in cancer. Ann Rev Pathol Mech Dis. 2009; 4: 127-150. 
168. Diaz-Meco MT, Abu-Baker S.  The Par-4/PTEN connection 
in tumor suppression. Cell Cycle. 2009; 8: 2518-2522. 
169. Mahimainathan L, Choudhury GG. Inactivation of platelet-
derived growth factor receptor by the tumor suppressor 
PTEN provides a novel mechanism of action of the 
phosphatase. J Biol Chem. 2004; 279: 15258-15268. 
170. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri 
S, Zeng S, Pagan J, Jeffery J, Puc J, Kumar R, Feng Z, 
Powell SN, Bhat A, Yaguchi T, Wadhwa R, et al. Cell 
cycle checkpoint defects contribute to genomic instability 
in PTEN deficient cells independent of DNA DSB repair. 
Cell Cycle. 2009; 8: 2198-2210. 
171. Poon JS, Eves R, Mak AS. Both lipid- and protein-
phosphatase activities of PTEN contribute to the p53-PTEN 
anti-invasion pathway. Cell Cycle. 2010; 9: 4450-4454. 
172. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, 
Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata 
JT. PTEN posttranslational inactivation and hyperactivation 
of the PI3K/Akt pathway sustain primary T cell leukemia 
viability. J Clin Invest. 2008; 118: 3762-3774.
173. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that 
directly dephosphorylates Akt, promotes apoptosis, and 
suppresses tumor growth. Mol Cell. 2005; 18: 13-24. 
174. Damen JE, Liu L, Rosten P, Humphries RK, Jefferson AB, 
Majerus PW, Krystal G.  The 145-kDa protein induced 
to associate with Shc by multiple cytokines is an inositol 
tetraphosphate and phosphatidylinositol 3,4,5-triposphate 
5-phosphatase. Proc Natl Acad Sci USA. 1996; 93: 1689-
1693. 
175. Lioubin MN, Algate PA, Tsai S, Carlberg K, Aebersold 
A, Rohrschneider LR. p150Ship, a signal transduction 
molecule with inositol polyphosphate-5-phosphatase 
activity. Genes & Devel. 1996; 10: 1084-1095. 
176. Muraille E, Pesesse X, Kuntz C, Erneux C. Distribution 
of the src-homology-2-domain-containing inositol 
5-phosphatase SHIP-2 in both non-haemopoietic and 
haemopoietic cells and possible involvement in SHIP-2 in 
negative signaling of B-cells. Biochem J. 1999; 342: 697-
705. 
177. Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert 
LM, Moodie S, Stokoe D. 5’phospholipid phosphatase 
SHIP-2 causes protein kinase B inactivation and cell cycle 
arrest in glioblastoma cells.  Mol Cell Biol. 2000; 20: 6860-
6871. 
178. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, 
Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda 
F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli 
AM. Cytotoxic activity of the novel Akt inhibitor, MK-
2206, in T-cell acute lymphoblastic leukemia. Leukemia. 
2012; May 22. doi: 10.1038/leu.2012.136
179. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation 
in hamartoma syndromes: therapeutic prospects. Cell Cycle. 
2009; 8: 403-413.
180. Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, 
Menendez JA. AMPK: Evidence for an energy-sensing 
cytokinetic tumor suppressor. Cell Cycle. 2009; 8: 3679-
3683.
181. Tamburini J, Green AS, Chapuis N, Bardet V, Lacombe 
C, Mayeux P, Bouscary D. Targeting translation in acute 
myeloid leukemia: a new paradigm for therapy? Cell Cycle. 
2009; 8: 3893-3899.
Oncotarget 2012; 3: 954-987979www.impactjournals.com/oncotarget
182. Sato T, Nakashima A, Guo L, Tamanoi F. Specific 
activation of mTORC1 by Rheb G-protein in vitro involves 
enhanced recruitment of its substrate protein. J Biol Chem. 
2009; 284: 12783-12791. 
183. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena 
L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, 
Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. 
Inhibition of mTORC1 leads to MAPK pathway activation 
through a PI3K-dependent feedback loop in human cancer. 
J Clin Invest. 2008; 118: 3065-3074. 
184. Martelli AM, Tabellini G, Ricci F, Evangelisti C, Chiarini F, 
Bortul R, McCubrey JA, Manzoli FA. PI3K/AKT/mTORC1 
and MEK/ERK signaling in T-cell acute lymphoblastic 
leukemia: New options for targeted therapy.  Adv Enzyme 
Regul. 2011; In Press.
185. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 
kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J 
Biol Chem. 2005; 280: 40406-40416.
186. Gomez-Baldo L, Schmidt S, Maxwell CA, Bonifaci N, 
Gabaldon T, Vidalain PO, Senapedis W, Kletke A, Rosing 
M, Barnekow A, Rottapel R, Capella G, Vidal M, Astrinidis 
A, Piekorz RP, Pujana MA. TACC3-TSC2 maintains 
nuclear envelope structure and controls cell division. Cell 
Cycle. 2010; 9: 1143-1155. 
187. Bhatia B, Nahle Z, Kenney AM. Double trouble: when 
sonic hedgehog signaling meets TSC inactivation. Cell 
Cycle. 2010; 9: 456-459. 
188. Kofman AE. McGraw MR. Payne CJ. Rapamycin increases 
oxidative stress response gene expression in adult stem 
cells.  Aging. 2012;4: 279-289.
189. Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Menendez 
JA. Raptor, a positive regulatory subunit of mTOR complex 
1, is a novel phosphoprotein of the rDNA transcription 
machinery in nucleoli and chromosomal nucleolus organizer 
regions (NORs). Cell Cycle. 2011; 10: 3140-3152. 
190. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang 
SA, Kuehl WM, Gray NS, Sabatini DM. DEPTOR is an 
mTOR inhibitor frequently overexpressed in multiple 
myeloma cells and required for their survival. Cell. 2009; 
137: 873-886.
191. Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H. LKB1 
and AMPK family signaling: the intimate link between cell 
polarity and energy metabolism. Physiol Rev. 2009; 89: 
777-798.
192. Shaw RJ,  Bardeesy N, Manning BD, Lopez L, Kosmatka 
M, DePinho RA, Cantley LC. The LKB1 tumor suppressor 
negatively regulates mTOR signaling. Cancer Cell. 2004; 6: 
91–99.
193. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, 
Depinho RA, Montminy M, Cantley LC. The kinase LKB1 
mediates glucose homeostasis in liver and therapeutic 
effects of metformin. Science. 2005; 310: 1642-1660.
194. van der Velden YU, Haramis AP. Insights from model 
organisms on the functions of the tumor suppressor protein 
LKB1: zebrafish chips in. Aging.  2011; 3: 363-367. 
195. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler 
S. microRNA-451: A conditional switch controlling glioma 
cell proliferation and migration. Cell Cycle. 2010; 9: 2742-
2748. 
196. Chen V, Shtivelman E.CC3/TIP30 regulates metabolic 
adaptation of tumor cells to glucose limitation. Cell Cycle. 
2010; 9: 4941-4953. 
197. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a 
target for cancer treatment. Cell Cycle. 2010; 9: 1091-1096.
198. Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A 
metabolic checkpoint that regulates the growth of EGFR 
activated glioblastomas. Cell Cycle. 2010; 9: 211-212. 
199. Saha AK, Xu XJ, Balon TW, Brandon A, Kraegen EW, 
Ruderman NB. Insulin resistance due to nutrient excess: is 
it a consequence of AMPK downregulation?.  Cell Cycle. 
2011; 10: 3447-3451.
200. Amato S, Man HY. Bioenergy sensing in the brain: the role 
of AMP-activated protein kinase in neuronal metabolism, 
development and neurological diseases. Cell Cycle. 2011; 
10: 3452-3460. 
201. Malik SA, Marino G, BenYounes A, Shen S, Harper F, 
Maiuri MC, Kroemer G. Neuroendocrine regulation of 
autophagy by leptin.Cell Cycle. 2011; 10: 2917-2923. 
202. Mounier R, Lantier L, Leclerc J, Sotiropoulos A, Foretz 
M, Viollet B. Antagonistic control of muscle cell size by 
AMPK and mTORC1. Cell Cycle. 2011; 10: 2640-2646. 
203. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Menendez 
JA. Polo-like kinase 1 regulates activation of AMP-
activated protein kinase (AMPK) at the mitotic apparatus. 
Cell Cycle. 2011; 10: 1295-1302. 
204. Polak, P, Cybulski N, Feige JN, Auwerx J, Rüegg MA, Hall 
MN. Adipose-specific knockout of raptor results in lean 
mice with enhanced mitochondrial respiration. Cell Metab. 
2008;  8: 399–410. 
205. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, 
Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, 
Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin 
fed late in life extends lifespan in genetically heterogeneous 
mice. Nature. 2009; 460: 392–395.
206. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, 
Morris AD. Metformin and reduced risk of cancer in 
diabetic patients. BMJ. 2005;330:1304–1305. 
 207. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: 
metabolism and growth control in tumour suppression. Nat 
Rev Cancer. 2009; 9: 563-575. 
208. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, 
de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson 
JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes 
JW, Wilkinson JE, et al. Rapamycin, but not resveratrol or 
simvastatin, extends life span of genetically heterogeneous 
mice. J Gerontol A Biol Sci Med Sci. 2011; 66: 191-201.
209. Liu B. Fan Z. Edgerton SM. Yang X, Lind SE, Thor 
AD. Potent anti-proliferative effects of metformin on 
Oncotarget 2012; 3: 954-987980www.impactjournals.com/oncotarget
trastuzumab-resistant breast cancer cells via inhibition of 
erbB2/IGF-1 receptor interactions. Cell Cycle. 2011; 10: 
2959-2966. 
210. Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary 
D, Tamburini J. LKB1/AMPK/mTOR signaling pathway in 
hematological malignancies: from metabolism to cancer cell 
biology. Cell Cycle. 2011; 10: 2115-2120. 
211. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Martin-
Castillo B, Menendez JA. Metformin activates an ataxia 
telangiectasia mutated (ATM)/Chk2-regulated DNA 
damage-like response. Cell Cycle. 2011; 10: 1499-1501. 
212. Mashhedi H, Blouin MJ, Zakikhani M, David S, Zhao Y, 
Bazile M, Birman E, Algire C, Aliaga A, Bedell BJ, Pollak 
M. Metformin abolishes increased tumor (18)F-2-fluoro-2-
deoxy-D-glucose uptake associated with a high energy diet. 
Cell Cycle. 2011; 10: 2770-2778. 
213.Oliveras-Ferraros C, Cufi S, Vazquez-Martin A, Torres-
Garcia VZ, Del Barco S, Martin-Castillo B, Menendez 
JA. Micro(mi)RNA expression profile of breast cancer 
epithelial cells treated with the anti-diabetic drug 
metformin: induction of the tumor suppressor miRNA 
let-7a and suppression of the TGFbeta-induced oncomiR 
miRNA-181a. Cell Cycle. 2011; 10: 1144-1451. 
214. Martin-Castillo B. Vazquez-Martin A. Oliveras-Ferraros C. 
Menendez JA. Metformin and cancer: doses, mechanisms 
and the dandelion and hormetic phenomena. Cell Cycle. 
2010; 9: 1057-1064. 
215. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-
Castillo B, Joven J, Menendez JA. Metformin against 
TGFβ-induced epithelial-to-mesenchymal transition 
(EMT): from cancer stem cells to aging-associated fibrosis. 
Cell Cycle. 2010; 9: 4461-4468. 
216. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, 
Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, 
Karkach AS, Romanyukha AA. Metformin extends life 
span of HER-2/neu transgenic mice and in combination 
with melatonin inhibits growth of transplantable tumors in 
vivo. Cell Cycle. 2010; 9: 188-197. 
217. Fuchs C, Rosner M, Dolznig H, Mikula M, Kramer N, 
Hengstschläger M. Tuberin and PRAS40 are anti-apoptotic 
gatekeepers during early human amniotic fluid stem-cell 
differentiation. Hum Mol Genet. 2012; 21: 1049-1061.
218. Oh WJ, Jacinto E. mTOR complex 2 signaling and 
functions. Cell Cycle. 2011; 10: 2305-2316. 
219. Memmott RM, Dennis PA. Akt-dependent and -independent 
mechanisms of mTOR regulation in cancer. Cell Signal. 
2009; 21: 656-664.
220. Rosner M, Hengstschlager M. mTOR protein localization is 
cell cycle-regulated.Cell Cycle. 2011; 10: 3608-3610. 
221. Jiang Y. mTOR goes to the nucleus. Cell Cycle. 2010;  9: 
868. 
222. Panieri E, Toietta G, Mele M, Labate V, Ranieri SC, 
Fusco S, Tesori V, Antonini A, Maulucci G, De Spirito 
M, Galeotti T, Pani G. Nutrient withdrawal rescues growth 
factor-deprived cells from mTOR-dependent damage. 
Aging. 2010; 2: 487-503. 
223. Lisse TS, Hewison M. Vitamin D: a new player in the world 
of mTOR signaling. Cell Cycle. 2011; 10: 1888-1889. 
224. Blagosklonny MV. Calorie restriction: decelerating mTOR-
driven aging from cells to organisms (including humans). 
Cell Cycle. 2010; 9: 683-638. 
225. Rodriguez A. Catalan V. Gomez-Ambrosi J. Fruhbeck 
G. Aquaglyceroporins serve as metabolic gateways in 
adiposity and insulin resistance control. Cell Cycle. 2011; 
10: 1548-1556.
226. Habib SL. Tuberin and mTOR, a key apoptotic pathway in 
diabetes. Cell Cycle. 2011; 10: 2237-2238.
227. Zeng LH, McDaniel S, Rensing NR, Wong M. Regulation 
of cell death and epileptogenesis by the mammalian target 
of rapamycin (mTOR): a double-edged sword? Cell Cycle. 
2010; 9: 2281-2285. 
228. D’Arcangelo G. Rapamycin treatment suppresses 
epileptogenic activity in conditional Pten knockout mice. 
Cell Cycle. 2010; 9: 2487-2488. 
229. Conn CS, Qian SB. mTOR signaling in protein homeostasis: 
less is more?. Cell Cycle. 2011; 10: 1940-1947. 
230. Tsang CK, Liu H, Zheng XF. mTOR binds to the promoters 
of RNA polymerase I- and III-transcribed genes. Cell Cycle. 
2010; 9: 953-957. 
231. Kantidakis T, White RJ. A feedback loop between mTOR 
and tRNA expression?. Cell Cycle. 2010; 9: 2934-2935. 
232. Dalvai M, Schubart K, Besson A, Matthias P. Oct1 is 
required for mTOR-induced G1 cell cycle arrest via the 
control of p27(Kip1) expression. Cell Cycle. 2010; 9: 3933-
3944. 
233. Salmond RJ, Zamoyska R. How does the mammalian target 
of rapamycin (mTOR) influence CD8 T cell differentiation? 
Cell Cycle. 2010; 9: 2952-2957.
234. Rao RR, Li Q, Shrikant PA. Fine-tuning CD8(+) T cell 
functional responses: mTOR acts as a rheostat for regulating 
CD8(+) T cell proliferation, survival and differentiation? 
Cell Cycle. 2010; 9: 2996-3001. 
235. Woods TC. Regulation of cell migration by mTOR is 
mediated through changes in p27Kip1 phosphorylation. 
Cell Cycle. 2010; 9: 2057-2058. 
236. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler 
S. microRNA-451: A conditional switch controlling glioma 
cell proliferation and migration. Cell Cycle. 2010; 9: 2742-
2748. 
237. Adhikari D, Liu K. mTOR signaling in the control of 
activation of primordial follicles. Cell Cycle. 2010; 9: 1673-
1674. 
238. Rodriguez-Jimenez FJ, Moreno-Manzano V, Mateos-
Gregorio P, Royo I, Erceg S, Murguia JR, Sanchez-Puelles 
JM. FM19G11: A new modulator of HIF that links mTOR 
activation with the DNA damage checkpoint pathways. Cell 
Cycle. 2010; 9: 2803-2813.
Oncotarget 2012; 3: 954-987981www.impactjournals.com/oncotarget
239. Leontieva OV, Blagosklonny MV. DNA damaging agents 
and p53 do not cause senescence in quiescent cells, while 
consecutive re-activation of mTOR is associated with 
conversion to senescence. Aging. 2010; 2: 924-935. 
240. Serrano M. Shifting senescence into quiescence by turning 
up p53. Cell Cycle. 2010; 9: 4256-4257. 
241. Romanov VS, Abramova MV, Svetlikova SB, Bykova 
TV, Zubova SG, Aksenov ND, Fornace AJ Jr, Pospelova 
TV, Pospelov VA.  p21(Waf1) is required for cellular 
senescence but not for cell cycle arrest induced by the 
HDAC inhibitor sodium butyrate. Cell Cycle. 2010; 9: 
3945-3955. 
242. Dulic V. Be quiet and you’ll keep young: does mTOR 
underlie p53 action in protecting against senescence by 
favoring quiescence? Aging. 2011; 3: 3-4. 
243. Wang C, Maddick M, Miwa S, Jurk D, Czapiewski R, 
Saretzki G, Langie SA, Godschalk RW, Cameron K, von 
Zglinicki T. Adult-onset, short-term dietary restriction 
reduces cell senescence in mice. Aging. 2010; 2: 555-566. 
244. Darzynkiewicz Z.  Another “Janus paradox” of p53: 
induction of cell senescence versus quiescence. Aging. 
2010; 2: 329-330. 
245. Schug TT. mTOR favors senescence over quiescence in 
p53-arrested cells.  Aging. 2010; 2: 327-328. 
246. Martins I, Galluzzi L, Kroemer G. Hormesis, cell death and 
aging. Aging. 2011; 3: 821-828. 
247. Galluzzi L, Kepp O, Kroemer G. Aging. TP53 and MTOR 
crosstalk to regulate cellular senescence. 2010; 2: 535-537. 
248. Narita M. Quality and quantity control of proteins in 
senescence.  Aging.  2010; 2: 311-314. 
249. Sahin M. Eph receptor and mTOR 
pathway crosstalk: implications for cancer. 
Cell Cycle. 2010; 9: 2053-2054. 
250. Gruppuso PA, Boylan JM, Sanders JA. The physiology and 
pathophysiology of rapamycin resistance: implications for 
cancer. Cell Cycle. 2011; 10: 1050-1058. 
251. Blagosklonny MV. Why the disposable soma theory cannot 
explain why women live longer and why we age. Aging. 
2010; 2: 884-887. 
252. Wesierska-Gadek J. mTOR and its link to the picture of 
Dorian Gray - re-activation of mTOR promotes aging. 
Aging. 2010; 2: 892-893. 
253. Zhao C, Vollrath D. mTOR pathway activation in age-
related retinal disease. Aging. 2011; 3: 346-347. 
254. Maki CG. Decision-making by p53 and mTOR .Aging. 
2010; 2: 324-326. 
255. Blagosklonny MV. Why men age faster but reproduce 
longer than women: mTOR and evolutionary perspectives. 
Aging. 2010; 2: 265-273. 
256. Blagosklonny MV. Why human lifespan is rapidly 
increasing: solving “longevity riddle” with “revealed-slow-
aging” hypothesis. Aging. 2010; 2: 177-182.
257. Blagosklonny MV. Rapamycin and quasi-programmed 
aging: four years later. Cell Cycle. 2010; 9: 1859-1862. 
258. Blagosklonny MV. Increasing healthy lifespan by 
suppressing aging in our lifetime: preliminary proposal. 
Cell Cycle. 2010; 9: 4788-4794. 
259. Foster DA. Reduced mortality and moderate alcohol 
consumption: the phospholipase D-mTOR connection.  Cell 
Cycle. 2010; 9: 1291-1294. 
260. Pani G. From growing to secreting: new roles for mTOR in 
aging cells. Cell Cycle. 2011; 10: 2450-2453. 
261. Santini E, Valjent E, Fisone G. mTORC1 signaling in 
Parkinson’s disease and L-DOPA-induced dyskinesia: A 
sensitized matter. Cell Cycle. 2010; 9: 2713-2718. 
262. Rambold AS, Lippincott-Schwartz J. Starved cells use 
mitochondria for autophagosome biogenesis. Cell Cycle. 
2010; 9: 3633-3634. 
263. Wu JJ, Quijano C, Wang J, Finkel 
T. Metabolism meets autophagy. 
Cell Cycle. 2010; 9: 4780-4781. 
264. Ciavarra G, Zacksenhaus E. Multiple pathways counteract 
cell death induced by RB1 loss: implications for cancer. 
Cell Cycle. 2011; 10: 1533-1539. 
265. Castello-Cros R, Bonuccelli G, Molchansky A, Capozza 
F, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, 
Whitaker-Menezes D, Sotgia F, Lisanti MP. Matrix 
remodeling stimulates stromal autophagy, “fueling” cancer 
cell mitochondrial metabolism and metastasis. Cell Cycle. 
2011; 10: 2021-2034. 
266. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes 
D, Daumer KM, Milliman JN. Chiavarina B, Migneco 
G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg 
N, Howell A, Pestell RG, Lisanti MP, Sotgia F. Tumor 
cells induce the cancer associated fibroblast phenotype via 
caveolin-1 degradation: implications for breast cancer and 
DCIS therapy with autophagy inhibitors. Cell Cycle. 2010; 
9: 2423-2433. 
267. Iozzo RV. Autophagic tumor stroma: a biofuel for cancer 
growth. Cell Cycle. 2011; 10: 3231-3232. 
268. Richardson AD, Scott DA. Reversing the Warburg effect 
through stromal autophagy. Cell Cycle. 2011; 10: 2830-
2831. 
269. Korkaya H, Wicha MS. Inflammation and autophagy 
conspire to promote tumor growth. Cell Cycle. 2011; 10: 
2623-2624. 
270. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides 
S, Chiavarina B, Bonuccelli G, Casey T, Tsirigos A, 
Migneco G, Witkiewicz A, Balliet R, Mercier I, Wang 
C, Flomenberg N, Howell A, Lin Z, Caro J, et al. The 
autophagic tumor stroma model of cancer or “battery-
operated tumor growth”: A simple solution to the autophagy 
paradox. Cell Cycle. 2010;  9: 4297-4306. 
271. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, 
Chiavarina B, Flomenberg N, Frank PG, Casimiro MC, 
Wang C, Pestell RG, Martinez-Outschoorn UE, Howell A, 
Sotgia F, Lisanti MP. The autophagic tumor stroma model 
Oncotarget 2012; 3: 954-987982www.impactjournals.com/oncotarget
of cancer: Role of oxidative stress and ketone production in 
fueling tumor cell metabolism. Cell Cycle. 2010; 9: 3485-
3505. 
272. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-
Outschoorn UE, Pavlides S, Howell A, Tanowitz HB, 
Casimiro MC, Wang C, Pestell RG, Grieshaber P, Caro 
J, Sotgia F, Lisanti MP. HIF1-alpha functions as a tumor 
promoter in cancer associated fibroblasts, and as a tumor 
suppressor in breast cancer cells: Autophagy drives 
compartment-specific oncogenesis. Cell Cycle. 2010; 9: 
3534-3551. 
273. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-
Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides 
S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, 
Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti 
MP, et al. Autophagy in cancer associated fibroblasts 
promotes tumor cell survival: Role of hypoxia, HIF1 
induction and NFkappaB activation in the tumor stromal 
microenvironment.Cell Cycle. 2010; 9: 3515-3533. 
274. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, 
Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell 
A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Ketones 
and lactate “fuel” tumor growth and metastasis: Evidence 
that epithelial cancer cells use oxidative mitochondrial 
metabolism. Cell Cycle. 2010; 9: 3506-3514.
275. Puissant A, Robert G, Auberger P. Targeting autophagy 
to fight hematopoietic malignancies. Cell Cycle. 2010; 9: 
3470-3478. 
276. Watson AS, Mortensen M, Simon AK. Autophagy in 
the pathogenesis of myelodysplastic syndrome and acute 
myeloid leukemia. Cell Cycle. 2011; 10: 1719-1725. 
277. Cluzeau T, Robert G, Puissant A, Jean-Michel K, Cassuto 
JP, Raynaud S, Auberger P. Azacitidine-resistant SKM1 
myeloid cells are defective for AZA-induced mitochondrial 
apoptosis and autophagy. Cell Cycle. 2011; 10: 2339-2343. 
278. Boehrer S, Lainey E, Kroemer G. Coordinated epigenetic 
regulation of autophagy and apoptosis. Cell Cycle. 2011; 
10: 2832-2833. 
279. Shen S, Kepp O, Martins I, Vitale I, Souquere S, Castedo 
M, Pierron G, Kroemer G. Defective autophagy associated 
with LC3 puncta in epothilone-resistant cancer cells. 
Cell Cycle. 2010; 9: 377-383. 
280. Galluzzi L, Morselli E, Kepp O, Maiuri MC, Kroemer G. 
Defective autophagy control by the p53 rheostat in cancer. 
Cell Cycle. 2010; 9: 250-255. 
281. García-Martínez JM, Alessi DR. mTOR complex 2 
(mTORC2) controls hydrophobic motif phosphorylation 
and activation of serum-and glucocorticoid-induced protein 
kinase 1 (SGK1). Biochem. J. 2008; 416: 375-385.  
282. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. 
Essential function of TORC2 in PKC and Akt turn motif 
phosphorylation, maturation and signalling. EMBO J. 2008; 
27: 1919-1931. 
283. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. 
mTOR, translation initiation and cancer. Oncogene. 2006; 
25: 6416-6422.
284. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation 
of mTORC2 by association with the ribosome. Cell. 2011; 
144; 757-768. 
285. Oh WJ, Wu CC, Kim SJ, Facchinetti V, Julien LA, Finlan 
M, Roux PP, Su B, Jacinto E. mTORC2 can associate with 
ribosomes to promote cotranslational phosphorylation and 
stability of nascent Akt polypeptide. EMBO J. 2010; 29: 
3939-3951. 
286. Oh WJ, Jacinto E. mTOR complex 2 signaling and 
functions. Cell Cycle. 2011; 10: 2305-2316. 
287. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin 
passes the torch: a new generation of mTOR inhibitors. Nat 
Rev Drug Discov. 2011; 10: 868-880.
288. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, 
Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, 
a novel binding partner of mTOR, defines a rapamycin-
insensitive and raptor-independent pathway that regulates 
the cytoskeleton. Curr Biol. 2004; 14: 1296-1302. 
289. Zhou H, Huang S. Role of mTOR signaling in tumor cell 
motility, invasion and metastasis. Curr Protein Pept Sci. 
2011; 12: 30-42. 
290. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the 
TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, 
insulin resistance, and cell survival deficiencies. Curr Biol. 
2004; 14: 1650-1656.
291. Lang SA, Hackl C, Moser C, Fichtner-Feigl S, Koehl 
GE, Schlitt HJ, Geissler EK, Stoeltzing O. Implication of 
RICTOR in the mTOR inhibitor-mediated induction of 
insulin-like growth factor-I receptor (IGF-IR) and human 
epidermal growth factor receptor-2 (Her2) expression in 
gastrointestinal cancer cells. Biochim Biophys Acta. 2010; 
1803: 435-442.
292. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell. 
2007; 12: 487-502.
293. Xu X, Sarikas A, Dias-Santagata DC, Dolios G, Lafontant 
PJ, Tsai SC, Zhu W, Nakajima H, Nakajima HO, Field 
LJ, Wang R, Pan ZQ. The CUL7 E3 ubiquitin ligase 
targets insulin receptor substrate 1 for ubiquitin-dependent 
degradation. Mol Cell. 2008; 30: 403-414.
294. Sriburi R, Jackowski S, Mori K, Brewer JW. XBP1: a link 
between the unfolded protein response, lipid biosynthesis, 
and biogenesis of the endoplasmic reticulum. J Cell Biol. 
2004; 167: 35-41.
295. Dibble CC, Asara JM, Manning BD. Characterization of 
Rictor phosphorylation sites reveals direct regulation of 
mTOR complex 2 by S6K1. Mol Cell Biol. 2009; 29: 5657-
5670.
296. Keniry M, Parsons R. The role of PTEN signaling 
perturbations in cancer and in targeted therapy. Oncogene. 
2008; 27: 5477-5485.
297. Stiles BL. Phosphatase and tensin homologue deleted on 
chromosome 10: extending its PTENtacles. Int J Biochem 
Oncotarget 2012; 3: 954-987983www.impactjournals.com/oncotarget
Cell Biol. 2009; 41: 757-761.
298. Kalesnikoff J, Sly LM, Hughes MR, Buchse T, Rauh MJ, 
Cao LP, Lam V, Mui A, Huber M, Krystal G. The role of 
SHIP in cytokine-induced signaling. Rev Physiol Biochem 
Pharmacol. 2003; 149: 87-103.
299. Eichhorn PJ, Creyghton MP, Bernards R. Protein 
phosphatase 2A regulatory subunits and cancer. Biochim 
Biophys Acta. 2009; 1795: 1-15.
300. Nolt JK, Rice LM, Gallo-Ebert C, Bisher ME, Nickels 
JT. PP2A (Cdc)55 is required for multiple events during 
meiosis. Cell Cycle. 2011; 10: 1420-134. 
301. Lee HJ, Hwang HI, Jang YJ. Mitotic DNA damage 
response: Polo-like kinase-1 is dephosphorylated through 
ATM-Chk1 pathway. Cell Cycle. 2010; 9: 2389-2398. 
302. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang 
CW. Regulation of phosphorylation of Thr-308 of Akt, cell 
proliferation, and survival by the B55a regulatory subunit 
targeting of the protein phosphatase 2A holoenzyme to Akt. 
J Biol Chem. 2008; 283: 1882-1892.
303. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo 
VR, Borthakur G, Konopleva M, Andreeff M, Kornblau 
SM. Low expression of PP2A regulatory subunit B55a is 
associated with T308 phosphorylation of AKT and shorter 
complete remission duration in acute myeloid leukemia 
patients. Leukemia. 2011; 25: 1711-1717.
304. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, 
Calasanz MJ, Odero MD. PP2A impaired activity is a 
common event in acute myeloid leukemia and its activation 
by forskolin has a potent anti-leukemic effect. Leukemia. 
2011; 25: 606-614.
305. Brognard J, Newton AC. PHLiPPing the switch on Akt and 
protein kinase C signaling. Trends Endocrinol Metab. 2008; 
19: 223-230.
306. Hirano I, Nakamura S, Yokota D, Ono T, Shigeno K, 
Fujisawa S, Shinjo K, Ohnishi K. Depletion of Pleckstrin 
homology domain leucine-rich repeat protein phosphatases 
1 and 2 by Bcr-Abl promotes chronic myelogenous 
leukemia cell proliferation through continuous 
phosphorylation of Akt isoforms. J Biol Chem. 2009; 284: 
22155-2165.
307. Demidenko ZN, Blagosklonny MV. The purpose of the 
HIF-1/PHD feedback loop: to limit mTOR-induced HIF-
1alpha. Cell Cycle. 2011; 10: 1557-1562. 
308. Rehn M, Cammenga J. (H)if blood stem cells gO2 sleep: 
what can wake them up?. Cell Cycle. 2011; 10: 3419-3420. 
309. Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, 
Shaw DP, Ma L, Brown A, Hoffman T, Rold TL, Atasoy 
U. Overexpression of the RNA binding protein HuR impairs 
tumor growth in triple negative breast cancer associated 
with deficient angiogenesis.  Cell Cycle. 2010; 9: 3337-
3346.
310. Thangarajah H, Vial IN, Grogan RH, Yao D, Shi Y, 
Januszyk M, Galiano RD, Chang EI, Galvez MG, Glotzbach 
JP, Wong VW, Brownlee M, Gurtner GC. HIF-1alpha 
dysfunction in diabetes. Cell Cycle. 2010; 9: 75-79. 
311. Mobasheri A, Richardson S, Mobasheri R, Shakibaei M, 
Hoyland JA. Hypoxia inducible factor-1 and facilitative 
glucose transporters GLUT1 and GLUT3: putative 
molecular components of the oxygen and glucose sensing 
apparatus in articular chondrocytes. Histol Histopathol. 
2005; 20: 1327-1338. 
312. Ousset M, Bouquet F, Fallone F, Biard D, Dray C, Valet P, 
Salles B, Muller C. Loss of ATM positively regulates the 
expression of hypoxia inducible factor 1 (HIF-1) through 
oxidative stress: Role in the physiopathology of the disease. 
Cell Cycle. 2010; 9: 2814-2822. 
313. Liu Y, Dean DC. Tumor initiation via loss of cell contact 
inhibition versus Ras mutation: do all roads lead to EMT? 
Cell Cycle. 2010; 9: 897-900. 
314. Wang J, Liu Y, Tan LX, Lo JC, Du J, Ryu MJ, Ranheim 
EA, Zhang J. Distinct requirements of hematopoietic stem 
cell activity and Nras G12D signaling in different cell types 
during leukemogenesis. Cell Cycle. 2011; 10: 2836-2839. 
315. Wang C, Lisanti MP, Liao DJ. Reviewing once more the 
c-myc and Ras collaboration: converging at the cyclin D1-
CDK4 complex and challenging basic concepts of cancer 
biology. Cell Cycle. 2011; 10: 57-67. 
316. Webb JD, Simon MC. Novel insights into the molecular 
origins and treatment of lung cancer. Cell Cycle. 2010; 9: 
4098-4105.
317. Shahbazian D, Parsyan A, Petroulakis E, Hershey J, 
Sonenberg N.  eIF4B controls survival and proliferation and 
is regulated by proto-oncogenic signaling pathways. Cell 
Cycle. 2010; 9: 4106-4109. 
318. de Magalhaes JP. A role for Ras signaling in modulating 
mammalian aging by the GH/IGF1 axis. Aging. 2011; 3: 
336-337. 
319. Borras C, Monleon D, Lopez-Grueso R, Gambini J, Orlando 
L, Pallardo FV, Santos E, Vina J, Font de Mora J.  RasGrf1 
deficiency delays aging in mice. Aging. 2011; 3: 262-276. 
320. Zhao L, Vogt PK. Hot-spot mutations in p110alpha 
of phosphatidylinositol 3-kinase (PI3K): differential 
interactions with the regulatory subunit p85 and with RAS. 
Cell Cycle. 2010; 9: 596-600. 
321. Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan 
SE. Elevated PI3K signaling drives multiple breast cancer 
subtypes. Oncotarget. 2011; 2: 435-447. 
322. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo 
S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, 
Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 
High frequency of mutations of the PIK3CA gene in human 
cancers. Science. 2004; 304: 554. 
323. Huang CH, Mandelker D, Gabelli SB, Amzel LM. Insights 
into the oncogenic effects of PIK3CA mutations from the 
structure of p110alpha/p85alpha. Cell Cycle 2008; 7: 1151-
1156. 
324. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam 
SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is 
Oncotarget 2012; 3: 954-987984www.impactjournals.com/oncotarget
frequently mutated in breast carcinomas and hepatocellular 
carcinomas. Oncogene. 2005; 24: 1477-1480. 
325. Shatyesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey 
T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. 
PIK3CA is implicated as an oncogene in ovarian cancer. 
Nat Genet. 1999; 21: 99-102. 
326. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile 
F, Nicoletti F, Stivala F, McCubrey JA, Libra M. PIK3CA 
mutations in human solid tumors. Cell Cycle. 2009: 8: 
1352-1358. 
327. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner 
EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic 
and prognostic significance of aberrant methylation in the 
molecular pathogenesis of human hepatocellular carcinoma. 
J Clin Invest. 2007; 117: 2713-2722. 
328. Steelman LS, Bertrand FE, McCubrey JA. The complexity 
of PTEN: mutation, marker and potential target for 
therapeutic intervention. Expert Opinion Ther Targets. 
2004; 8: 537-550. 
329. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, 
Boyd J. Mutation analysis of the putative tumor suppressor 
gene PTEN/MMAC1 in primary breast carcinomas. Cancer 
Res. 1997; 57: 3657-3659.
330. Singh B, Ittmann MM, Krolewski JJ. Sporadic breast 
cancers exhibit loss of heterozygosity on chromosome 
segment 10q23 close to the Cowden disease locus. Genes 
Chromosome Can. 1998; 21: 166-171.
331. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-
Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-
Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, 
Kim HJ, Misteli T, Jiang X, Pandolfi PP. Ubiquitination 
regulates PTEN nuclear import and tumor suppression. 
Cell. 2007; 128: 141-156.
332. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri 
S, Zeng S, Pagan J, Jeffery J, Puc J, Kumar R, Feng Z, 
Powell SN, Bhat A, Yaguchi T, Wadhwa R, et al. Cell 
cycle checkpoint defects contribute to genomic instability 
in PTEN deficient cells independent of DNA DSB repair. 
Cell Cycle. 2009; 8: 2198-2210.
333. Kappes H, Goemann C, Bamberger AM, Löning T, Milde-
Langosch K. PTEN expression in breast and endometrial 
cancer: correlation with steroid hormone receptor status. 
Pathobiology. 2001; 69: 136-142. 
334. Suzuki A, Nakano T, Mak TW, Sasaki T. Portrait of PTEN: 
messages from mutant mice. Cancer Sci. 2008; 99: 209-213. 
335. Yao YJ, Ping XL, Zhang H, Chen FF, Lee PK, Ahsan H, 
Chen CJ, Lee PH, Peacocke M, Santella RM, Tsou HC. 
PTEN/MMAC1 mutations in hepatocellular carcinomas. 
Oncogene. 1999; 18: 3181-3185. 
336. Yeh KT, Chang JG, Chen YJ, Chen ST, Yu SY, Shih MC, 
Perng LI, Wang JC, Tsai M, Chang CP. Mutation analysis 
of the putative tumor suppressor gene PTEN/MMAC1 in 
hepatocellular carcinoma. Cancer Invest. 2000; 18: 123-
129. 
337. Kawamura N, Nagai H, Bando K, Koyama M, Matsumoto 
S, Tajiri T, Onda M, Fujimoto J, Ueki T, Konishi N, Shiba 
T, Emi M. PTEN/MMAC1 mutations in hepatocellular 
carcinomas: somatic inactivation of both alleles in tumors. 
Jpn J Cancer Res. 1999; 90: 413-418.
338. Fujiwara Y, Hoon DS, Yamada T, Umeshita K, Gotoh 
M, Sakon M, Nishisho I, Monden M. PTEN/MMAC1 
mutation and frequent loss of heterozygosity identified in 
chromosome 10q in a subset of hepatocellular carcinomas. 
Jpn J Cancer Res. 2000; 91: 287-292.
339. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li 
QL. Epigenetic and genetic alterations of PTEN in 
hepatocellular carcinoma. Hepatol Res. 2007; 37: 389-396. 
340. Rahman MA, Kyriazanos ID, Ono T, Yamanoi A, Kohno 
H, Tsuchiya M, Nagasue N. Impact of PTEN expression 
on the outcome of hepatitis C virus-positive cirrhotic 
hepatocellular carcinoma patients: possible relationship 
with COX II and inducible nitric oxide synthase. Int J 
Cancer. 2002; 100: 152-157. 
341. Hu TH, Wang CC, Huang CC, Chen CL, Hung CH, Chen 
CH, Wang JH, Lu SN, Lee CM, Changchien CS, Tai 
MH. Down-regulation of tumor suppressor gene PTEN, 
overexpression of p53, plus high proliferating cell nuclear 
antigen index predict poor patient outcome of hepatocellular 
carcinoma after resection. Oncol Rep. 2007; 18: 1417-1426. 
342. Chung TW, Lee YC, Ko JH, Kim CH. Hepatitis B Virus 
X protein modulates the expression of PTEN by inhibiting 
the function of p53, a transcriptional activator in liver cells. 
Cancer Res. 2003; 63: 3453-3458. 
343. Kang-Park S, Im JH, Lee JH, Lee YI. PTEN modulates 
hepatitis B virus-X protein induced survival signaling in 
Chang liver cells. Virus Res. 2006; 122: 53-60. 
344. Butler MP, Wang SI, Chaganti RS, Parsons R, Dalla-Favera 
R. Analysis of PTEN mutations and deletions in B-cell non-
Hodgkin‘s lymphomas. Genes Chromosomes Cancer. 1999; 
24: 322-327.
345. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld 
M. PTEN gene alterations in lymphoid neoplasms. Blood. 
1998; 92: 3410-3415. 
346. Uddin S, Hussain A, Al Hussein K, Platanias LC, Bhatia 
KG. Inhibition of phosphatidylinositol 3‘-kinase induces 
preferentially killing of PTEN-null T leukemias through 
AKT pathway. Biochem Biophys Res Commun. 2004; 320: 
932-938.
347. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, 
Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, 
Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, 
Cordon-Cardo C, et al. Mutational loss of PTEN induces 
resistance to NOTCH1 inhibition in T-cell leukemia. Nat 
Med. 2007; 13: 1203-1210. 
348. Palomero T, Dominguez M, Ferrando AA. The role of the 
PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell 
Cycle. 2008; 7: 965-970. 
349. Garcia JM, Silva J, Pena C, Garcia V, Rodríguez R, Cruz 
Oncotarget 2012; 3: 954-987985www.impactjournals.com/oncotarget
MA, Cantos B, Provencio M, España P, Bonilla F. Promoter 
methylation of the PTEN gene is a common molecular 
change in breast cancer. Genes Chromosomes Cancer. 
2004; 41: 117-124. 
350. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era 
S, Mori M. Reduced expression of PTEN protein and its 
prognostic implications in invasive ductal carcinoma of the 
breast. Oncology. 2005; 68: 398-404.
351.Yang H, Kong W, Zhao JJ, O‘Donnell JD, Wang J. 
MicroRNA expression profiling in human ovarian cancer: 
miR-274 induces cell survival and cisplatin resistance by 
targeting PTEN. Cancer Res. 2008; 68: 425-433. 
352. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward 
R, Savage K, Delmas V, Larue L, Pritchard C, Marais 
R. Oncogenic Braf induces melanocyte senescence and 
melanoma in mice. Cancer Cell. 2009; 15: 294-303. 
353. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis 
AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, 
Bosenberg M. Braf(V600E) cooperates with PTEN loss to 
induce metastatic melanoma. Nat Genet. 2009; 41: 544-552. 
354. Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno 
K, Hanamura I, Miura K, Iida S, Ueda R, Naoe T, Akao Y, 
Ohno R, Ohnishi K. Possible dominant-negative mutation 
of the SHIP gene in acute myeloid leukemia. Leukemia. 
2003; 17: 1-8. 
355. Metzner A, Horstmann MA, Fehse B, Ortmeyer G, 
Niemeyer CM, Stocking C,  Mayr GW, Jücker M. Gene 
transfer of SHIP-1 inhibits proliferation of juvenile 
myelomonocytic leukemia cells carrying KRAS2 or 
PTPN11 mutations. Gene Ther. 2007; 14: 699-703. 
356.Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke 
TF, Hamilton TC, Tsichlis PN, Testa JR. AKT2, a putative 
oncogene encoding a member of a subfamily of protein-
serine/threonine kinases, is amplified in human ovarian 
carcinomas. Proc Natl Acad Sci USA. 1992; 89: 9267-9271. 
357. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, 
Robbins CM, Hostetter G, Boguslawski S, Moses TY, 
Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, 
Tucker-Kellog G, et al. A transforming mutation in the 
pleckstrin homology domain of AKT1 in cancer. Nature. 
2007; 448: 439-444. 
358. Stemke-Hale K, Gonzalez-Angelo M, Lhuch A Neve RM, 
Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, 
Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns 
K, Hung MC, et al. An integrative genomic and proteomic 
analysis of PIK3CA, PTEN and Akt mutations in breast 
cancer. Cancer Res. 2008; 68: 6084-6091. 
359. Bellacosa A, DeFeo D, Godwin AK, Bell DW, Cheng JQ, 
Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo 
V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, 
Testa JR. Molecular alterations of the Akt oncogene in 
breast cancer. Int J Cancer. 1995; 64: 280-285. 
360. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng 
W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB.  A 
novel Akt3 mutation in melanoma tumours and cell lines. 
Brit J Cancer. 2008; 99: 1265-1268. 
361. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, 
Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins 
S, O’Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe 
S, et al. Patterns of somatic mutation in human cancer 
genomes.  Nature. 2007; 446:153-158.
362. Do H, Salemi R, Murone C, Mitchell PL, Dobrovic A. 
Rarity of AKT1 and AKT3 E17K mutations in squamous 
cell carcinoma of lung. Cell Cycle. 2010; 9: 4411-4412. 
363. Karst AM, Dai DL, Cheng JQ, Li G.  Role of p53 up-
regulated modulator of apoptosis and phosphorylated Akt 
in melanoma cell growth, apoptosis and patient survival. 
Cancer Res. 2006; 66: 9221-9226. 
364. Slipicevic A, Holm R, Nguyen MTP, Bøhler PJ, Davidson 
B, Flørenes VA.  Expression of activated Akt and PTEN in 
malignant melanomas: Relationship with clinical outcome. 
Am J Clin Pathol. 2005; 124: 528-536.
365. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, 
Wang H, Unger M, Testa JR. Frequent activation of AKT in 
non-small cell lung carcinomas and preneoplastic bronchial 
lesions.  Carcinogenesis. 2004; 25: 2053-2059. 
366. Benavides F, Blando J, Perez CJ, Garg R, Conti CJ, 
DiGiovanni J, Kazanietz MG. Transgenic overexpression 
of PKCepsilon in the mouse prostate induces preneoplastic 
lesions. Cell Cycle. 2011; 10: 268-277. 
367. Basu A.  PKCepsilon paves the way for prostate cancer. 
Cell Cycle. 2011; 10: 378. 
368. Knudsen KE. A tale of three PKCs: epsilon emerges as a 
driver of pre-neoplastic phenotypes. Cell Cycle. 2011; 10: 
379.
369. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, 
Testa JR. AKT activation up-regulates insulin-like growth 
factor I receptor expression and promotes invasiveness of 
human pancreatic cancer cells. Cancer Res. 2001; 61: 589-
593. 
370. St-Germain ME, Gagnon V, Parent S, Asselin E. Regulation 
of COX-2 protein expression by Akt in endometrial cancer 
cells is mediated through NF-kB/IkB pathway.  Mol Cancer. 
2004; 3: 7. 
371. Chefetz I, Holmberg JC, Alvero AB, Visintin I, Mor G. 
Inhibition of Aurora-A kinase induces cell cycle arrest 
in epithelial ovarian cancer stem cells by affecting NFkB 
pathway. Cell Cycle. 2011; 10: 2206-2214. 
372. Iwai K.  Linear polyubiquitin chains: a new modifier 
involved in NFkappaB activation and chronic inflammation, 
including dermatitis. Cell Cycle. 2011; 10: 3095-3104. 
373. Melvin A, Mudie S, Rocha S. Further insights into the 
mechanism of hypoxia-induced NFkappaB. Cell Cycle. 
2011; 10: 879-882.
374. Madge LA, May MJ. The NFkappaB paradox: RelB induces 
and inhibits gene expression. Cell Cycle. 2011; 10: 6-7. 
375. Oren M, Cooks T. NFkappaB and p53: A life and death 
affair. Cell Cycle. 2010;  9: 1027. 
Oncotarget 2012; 3: 954-987986www.impactjournals.com/oncotarget
376. Barre B, Perkins ND. Phosphorylation 
of the p52 NF-kappaB subunit. 
Cell Cycle. 2010; 9: 4774-4775. 
377. Barre B, Coqueret O, Perkins ND. Regulation of activity 
and function of the p52 NF-kappaB subunit following DNA 
damage. Cell Cycle. 2010; 9: 4795-4804. 
378. Lamprecht B, Bonifer C, Mathas S. Repeat-element driven 
activation of proto-oncogenes in human malignancies. Cell 
Cycle. 2010; 9: 4276-4281. 
379. Martin AG. NFkappaB anti-apoptotic or pro-apoptotic, 
maybe both. Cell Cycle. 2010; 9: 3131-3132. 
380. O’Prey J, Crighton D, Martin AG, Vousden KH, Fearnhead 
HO. Ryan KM. p53-mediated induction of Noxa and 
p53AIP1 requires NFkappaB. Cell Cycle. 2010; 9: 947-952. 
381. Vaughan S, Jat PS. Deciphering the role of nuclear factor-
kappaB in cellular senescence.  Aging. 2011; 3: 913-919. 
382. Moskalev A, Shaposhnikov M. Pharmacological 
inhibition of NF-kappaB prolongs lifespan of Drosophila 
melanogaster. Aging. 2011; 3: 391-394. 
383. Hofseth LJ, Singh UP, Singh NP, Nagarkatti M, Nagarkatti 
PS. Taming the beast within: resveratrol suppresses colitis 
and prevents colon cancer. Aging. 2010; 2: 183-184. 
384. Chow S, Minden MD, Hedley DW. Constitutive 
phosphorylation of the S6 ribosomal protein via mTOR and 
ERK signaling in the peripheral blasts of acute leukemia 
patients. Exp Hematol. 2006; 34: 1183-1191. 
385. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/
Akt is constitutively active in primary acute myeloid 
leukaemia cells and regulates survival and chemoresistance 
via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 
2005; 19: 586-594. 386. Ricciardi MR, McQueen T, 
Chism D, Milella M, Estey E, Kaldjian E, Sebolt-Leopold 
J, Konopleva M, Andreeff M. Quantitative single cell 
determination of ERK phosphorylation and regulation in 
relapsed and refractory primary acute myeloid leukemia. 
Leukemia. 2005; 19: 1543-1549. 
387. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi 
P, Bonati A, Bonati A, Cervello M, Lee JT, Steelman LS. 
Targeting the Raf/MEK/ERK pathway with small molecule 
inhibitors. Current Opinion Investigational Drugs. 2008; 9: 
614-630.
388. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, 
Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, 
Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, 
Cervello M. Emerging MEK Inhibitors. Exp Opin Emerging 
Drugs. 2010; 15: 203-223. 
389. Yun C, Cho H, Kim SJ, Lee JH, Park SY, Chan GK, Cho H. 
Mitotic aberration coupled with centrosome amplification 
is induced by hepatitis B virus X oncoprotein via the Ras-
mitogen-activated protein/extracellular signal-regulated 
kinase-mitogen-activated protein pathway. Mol Cancer Res. 
2004; 2: 159-169.
390. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin 
YW, Changchien CS, Lee CM, Tai MH. Expression and 
prognostic role of tumor suppressor gene PTEN/MMAC1/
TEP1 in hepatocellular carcinoma. Cancer. 2003; 97: 1929-
1940. 
391.Lee YI, Kang-Park S, Do SI, Lee YI. The hepatitis B virus-X 
protein activates a phosphatidylinositol 3-kinase-dependent 
survival signaling cascade. J Biol Chem. 2001; 276: 16969-
16977. 
392. Mannová P, Beretta L. Activation of the N-Ras-PI3K-Akt-
mTOR pathway by hepatitis C virus: control of cell survival 
and viral replication. J Virol. 2005; 79: 8742-8749. 
393. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation 
in hamartoma syndromes: therapeutic prospects. Cell Cycle. 
2009; 8: 403-413.
394. Knowles MA, Platt FM, Ross RL, Hurst CD. 
Phosphatidylinositol 3-kinase (PI3K) pathway activation in 
bladder cancer. Cancer Metastasis Rev. 2009; 28: 305-316.
395. Graff JR, Zimmer SG. Translational control and metastatic 
progression: enhanced activity of the mRNA cap-binding 
protein eIF-4E selectively enhances translation of 
metastasis-related mRNAs. Clin Exp Metastasis. 2003; 20: 
265-273. 
396. Zimmer SG, DeBenedetti A, Graff JR. Translational control 
of malignancy: the mRNA cap-binding protein, eIF-4E, as a 
central regulator of tumor formation, growth, invasion and 
metastasis. Anticancer Res. 2000; 20: 1343-1351. 
397. Galmozzi E, Casalini P, Iorio MV, Casati B, Olgiati C, 
Menard S. HER2 signaling enhances 5’UTR-mediated 
translation of c-Myc mRNA. J Cell Physiol. 2004; 200: 82-
88. 
398. Podar K, Anderson KC.  A therapeutic role for targeting 
c-Myc/Hif-1-dependent signaling pathways. Cell Cycle. 
2010; 9: 1722-1728. 
399. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu 
JH, Sawyers CL, Lichtenstein AK. AKT activity determines 
sensitivity to mammalian target of rapamycin (mTOR) 
inhibitors by regulating cyclin D1 and c-myc expression. J 
Biol Chem. 2004; 279: 2737-2746. 
400. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio 
AM. Integrin (alpha 6 beta 4) regulation of eIF-4E activity 
and VEGF translation: a survival mechanism for carcinoma 
cells. J Cell Biol. 2002; 158: 165-174. 
401. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-
Cardo C. Overexpression of cyclin D1 is associated with 
metastatic prostate cancer to bone. Clin Cancer Res. 2000; 
6: 1891-1895. 
402. Dunsmuir WD, Gillett CE, Meyer LC, Young MP, 
Corbishley C, Eeles RA, Kirby RS. Molecular markers 
for predicting prostate cancer stage and survival. BJU Int. 
2000; 6: 869-878. 
403. Gallant P, Steiger D. Myc’s secret life without Max. Cell 
Cycle. 2009; 8: 3848-3853. 
404. Hydbring P, Larsson LG. Cdk2: a key regulator of the 
senescence control function of Myc. Aging. 2010; 2: 244-
250.
Oncotarget 2012; 3: 954-987987www.impactjournals.com/oncotarget
405. Jin J, Wang GL, Timchenko L, Timchenko NA. GSK3beta 
and aging liver. Aging. 2009; 1: 582-585. 
406. Gan B, DePinho RA. mTORC1 signaling governs 
hematopoietic stem cell quiescence.  Cell Cycle. 2009; 8: 
1003-1006. 
407. Lluis F, Cosma MP.  Somatic cell reprogramming control: 
signaling pathway modulation versus transcription factor 
activities. Cell Cycle. 2009; 8: 1138-1144. 
408. Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James 
CD, Couch FJ. 17q23 amplifications in breast cancer 
involve the PAT1, RAD51C, PS6K and SIGma1B genes. 
Cancer Res. 2000; 60: 5371-5375. 
409. Barlund M, Forozan F, Kononen J, Bubendorf L, Chen 
Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, 
Kallioniemi OP, Kallioniemi A. Detecting activation of 
ribosomal protein S6 kinase by complementary DNA and 
tissue microarray analysis. J Natl Cancer Inst. 2000; 92: 
1252-1259. 
410. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas 
G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. 
Enhanced sensitivity of PTEN-deficient tumors to inhibition 
of FRAP/mTOR. Proc Natl Acad Sci USA. 2001; 98: 
10314-10319.
